1
|
Herrera MC, Johnson J, Lim S, Morales KH, Wilson JD, Hadland SE, Metzger D, Wood S, Dowshen N. Co-delivery of HIV pre-exposure prophylaxis (PrEP) and HIV testing among publicly insured adolescents and young adults (AYA) receiving medication for opioid use disorder (MOUD). Drug Alcohol Depend 2024; 257:111132. [PMID: 38387256 PMCID: PMC11031309 DOI: 10.1016/j.drugalcdep.2024.111132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Revised: 01/22/2024] [Accepted: 02/12/2024] [Indexed: 02/24/2024]
Abstract
BACKGROUND Low rates of HIV pre-exposure prophylaxis (PrEP) prescribing contribute to the disproportionate burden of HIV in the United States. Among adolescent and young adults (AYA) with opioid use disorder, HIV testing and PrEP co-prescription rates are poorly characterized. METHODS We performed a retrospective analysis involving deidentified data from Philadelphia's Medicaid beneficiaries ages 16-29 years who were prescribed medication for opioid use disorder (MOUD) from 2015 to 2020 and continuously Medicaid-enrolled for ≥6 months prior to that prescription. After identifying the presence of a qualifying diagnosis signifying a PrEP indication, we examined the outcome of appropriate PrEP co-prescriptions and HIV testing using generalized estimating equations (GEE) modeling. RESULTS We identified 795 AYA Medicaid beneficiaries with 1269 qualified treatment episodes. We calculated a PrEP prescribing rate of 29.47 per 1000 person-years among AYA receiving MOUD. The HIV testing rate was 63.47 per 1000 person-years among AYA receiving MOUD. GEE modeling revealed that individuals receiving methadone were more likely (aOR=2.62, 95% CI=1.06-6.49) to receive HIV testing within 6 months after a PrEP-qualifying diagnosis compared to those receiving other MOUD medications. Those who only saw outpatient behavioral health providers were less likely (aOR=0.48, 95% CI=0.24-0.99) to have received an HIV test within 6 months after the PrEP-qualifying diagnosis compared to those receiving inpatient behavioral health services. CONCLUSIONS Co-prescription of PrEP and HIV testing among AYA receiving MOUD was rare in this large urban publicly insured population. Interventions are needed to increase HIV prevention services for this key population of AYA at risk for HIV infection.
Collapse
Affiliation(s)
- M C Herrera
- Division of Adolescent Medicine, Department of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
| | - J Johnson
- Department of Behavioral Health and Intellectual disAbility Services, Philadelphia, PA, USA
| | - S Lim
- Department of Behavioral Health and Intellectual disAbility Services, Philadelphia, PA, USA
| | - K H Morales
- Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - J Deanna Wilson
- Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - S E Hadland
- Division of Adolescent and Young Adult Medicine, MassGeneral for Children / Harvard Medical School, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA
| | - D Metzger
- Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - S Wood
- Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - N Dowshen
- Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
2
|
Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol 2024; 25:308-316. [PMID: 38423047 DOI: 10.1016/s1470-2045(24)00020-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 01/09/2024] [Accepted: 01/10/2024] [Indexed: 03/02/2024]
Abstract
BACKGROUND Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive alternative for patients with primary renal cell cancer who do not undergo surgical resection. The FASTRACK II clinical trial investigated the efficacy of SABR for primary renal cell cancer in a phase 2 trial. METHODS This international, non-randomised, phase 2 study was conducted in seven centres in Australia and one centre in the Netherlands. Eligible patients aged 18 years or older had biopsy-confirmed diagnosis of primary renal cell cancer, with only a single lesion; were medically inoperable, were at high risk of complications from surgery, or declined surgery; and had an Eastern Cooperative Oncology Group performance status of 0-2. A multidisciplinary decision that active treatment was warranted was required. Key exclusion criteria were a pre-treatment estimated glomerular filtration rate of less than 30 mL/min per 1·73 m2, previous systemic therapies for renal cell cancer, previous high-dose radiotherapy to an overlapping region, tumours larger than 10 cm, and direct contact of the renal cell cancer with the bowel. Patients received either a single fraction SABR of 26 Gy for tumours 4 cm or less in maximum diameter, or 42 Gy in three fractions for tumours more than 4 cm to 10 cm in maximum diameter. The primary endpoint was local control, defined as no progression of the primary renal cell cancer, as evaluated by the investigator per Response Evaluation Criteria in Solid Tumours (version 1.1). Assuming a 1-year local control of 90%, the null hypothesis of 80% or less was considered not to be worthy of proceeding to a future randomised controlled trial. All patients who commenced trial treatment were included in the primary outcome analysis. This trial is registered with ClinicalTrials.gov, NCT02613819, and has completed accrual. FINDINGS Between July 28, 2016, and Feb 27, 2020, 70 patients were enrolled and initiated treatment. Median age was 77 years (IQR 70-82). Before enrolment, 49 (70%) of 70 patients had documented serial growth on initial surveillance imaging. 49 (70%) of 70 patients were male and 21 (30%) were female. Median tumour size was 4·6 cm (IQR 3·7-5·5). All patients enrolled had T1-T2a and N0-N1 disease. 23 patients received single-fraction SABR of 26 Gy and 47 received 42 Gy in three fractions. Median follow-up was 43 months (IQR 38-60). Local control at 12 months from treatment commencement was 100% (p<0·0001). Seven (10%) patients had grade 3 treatment-related adverse events, with no grade 4 adverse events observed. Grade 3 treatment-related adverse events were nausea and vomiting (three [4%] patients), abdominal, flank, or tumour pain (four [6%]), colonic obstruction (two [3%]), and diarrhoea (one [1%]). No treatment-related or cancer-related deaths occurred. INTERPRETATION To our knowledge, this is the first multicentre prospective clinical trial of non-surgical definitive therapy in patients with primary renal cell cancer. In a cohort with predominantly T1b or larger disease, SABR was an effective treatment strategy with no observed local failures or cancer-related deaths. We observed an acceptable side-effect profile and renal function after SABR. These outcomes support the design of a future randomised trial of SABR versus surgery for primary renal cell cancer. FUNDING Cancer Australia Priority-driven Collaborative Cancer Research Scheme.
Collapse
Affiliation(s)
- Shankar Siva
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia.
| | - Mathias Bressel
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia
| | - Mark Sidhom
- Department of Radiation Oncology, Liverpool Hospital, Liverpool, NSW, Australia; South West Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia
| | - Swetha Sridharan
- Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia
| | - Ben G L Vanneste
- Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, Netherlands; Department of Human Structure and Repair, Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
| | - Ryan Davey
- TransTasman Radiation Oncology Group, Waratah, NSW, Australia
| | | | - Jeremy Ruben
- Department of Radiation Oncology, Alfred Health Radiation Oncology, Melbourne, VIC, Australia; Central Clinical School, Monash University, Melbourne, VIC, Australia
| | - Farshad Foroudi
- Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Heidelberg, VIC, Australia
| | - Braden Higgs
- Department of Radiation Oncology, Royal Adelaide Hospital, South Australia, Australia; Department of Radiation Oncology, University of South Australia, Adelaide, SA, Australia
| | - Charles Lin
- Department of Radiation Oncology, Royal Brisbane and Women's Hospital, QLD, Australia; University of Queensland, Brisbane, QLD, Australia
| | - Avi Raman
- Department of Urology, John Hunter Hospital, Newcastle, NSW, Australia; The University of Newcastle, NSW, Australia
| | - Nicholas Hardcastle
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia
| | - Michael S Hofman
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia
| | - Richard De Abreu Lourenco
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, NSW, Australia
| | - Mark Shaw
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Pascal Mancuso
- Department of Urology, Liverpool Hospital, Liverpool, NSW, Australia
| | - Daniel Moon
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Royal Melbourne Clinical School, University of Melbourne, VIC, Australia
| | - Lih-Ming Wong
- Department of Surgery, University of Melbourne, VIC, Australia; Department of Urology, St Vincent's Health, Melbourne, VIC, Australia
| | - Nathan Lawrentschuk
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Department of Surgery, University of Melbourne, VIC, Australia
| | - Simon Wood
- University of Queensland, Brisbane, QLD, Australia; Department of Urology and Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
| | - Nicholas R Brook
- Department of Urology, Royal Adelaide Hospital, South Australia, Australia; Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia
| | - Tomas Kron
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia
| | - Jarad Martin
- Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia; The University of Newcastle, NSW, Australia
| | - David Pryor
- Department of Urology and Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia; Queensland University of Technology, Brisbane, QLD, Australia
| |
Collapse
|
3
|
Bland D, Evans R, Binesmael A, Wood S, Qureshi SP, Fearnley K, Small A, Strain WD, Agius R. Post-acute COVID-19 complications in UK doctors: results of a cross-sectional survey. Occup Med (Lond) 2024; 74:99-103. [PMID: 38078498 DOI: 10.1093/occmed/kqad120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2024] Open
Abstract
BACKGROUND As a consequence of their occupation, doctors and other healthcare workers were at higher risk of contracting coronavirus disease 2019 (COVID-19), and more likely to experience severe disease compared to the general population. However, systematic information on post-acute COVID complications in doctors is very limited. AIMS This study aimed to determine the symptoms, perceived determinants, health and occupational impact, and consequent needs relating to post-acute COVID complications in UK doctors. METHODS An online cross-sectional survey was distributed to UK doctors self-identifying as having Long COVID or other post-acute COVID complications. RESULTS Of 795 responses, 603 fulfilled the inclusion criteria of being a UK-based medical doctor experiencing one or more post-acute COVID complications. Twenty-eight per cent reported a lack of adequate Respiratory Protective Equipment at the time of contracting COVID-19. Eighteen per cent of eligible respondents reported that they had been unable to return to work since acquiring COVID. CONCLUSIONS Post-acute COVID (Long COVID) in UK doctors is a substantial burden for respondents to our questionnaire. The results indicated that insufficient respiratory protection could have contributed to occupational disease, with COVID-19 being contracted in the workplace, and resultant post-COVID complications. Although it may be too late to address the perceived determinants of inadequate protection for those already suffering with Long COVID, more investment is needed in rehabilitation and support of those afflicted.
Collapse
Affiliation(s)
- D Bland
- Public Health and Healthcare Department, British Medical Association, London, UK
| | - R Evans
- Public Health and Healthcare Department, British Medical Association, London, UK
| | - A Binesmael
- Public Health and Healthcare Department, British Medical Association, London, UK
| | - S Wood
- Public Health and Healthcare Department, British Medical Association, London, UK
| | | | - K Fearnley
- Long COVID Doctors for Action, London, UK
| | - A Small
- Chest Heart and Stroke Scotland, Edinburgh, UK
| | - W D Strain
- British Medical Association Board of Science, University of Exeter Medical School, Institute of Clinical and Biomedical Science, Exeter, UK
| | - R Agius
- Council of the British Medical Association, The University of Manchester, Manchester, UK
| |
Collapse
|
4
|
Ferraby DH, Hayhurst D, Strachan R, Knapman H, Wood S, Fallowfield JL. Musculoskeletal injuries in UK Service Personnel and the impact of in-theatre rehabilitation during Cold Weather Warfare training: Exercise CETUS 2020. BMJ Mil Health 2023; 169:517-522. [PMID: 35042762 DOI: 10.1136/bmjmilitary-2021-001972] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Accepted: 12/07/2021] [Indexed: 11/04/2022]
Abstract
INTRODUCTION The Royal Marines provide the lead Service for UK Defence Mountain and Cold Weather Warfare capability. This is the first prospective study addressing musculoskeletal injury rates sustained during Cold Weather Warfare training, with the aim of informing injury mitigation interventions and assist military medical planning with respect to delivering primary care rehabilitation in theatre. METHODS All musculoskeletal injuries were surveyed by the Forward Rehabilitation Team (Nov 2019-Mar 2020) during a Cold Weather Deployment to Norway (Ex CETUS 2019/20). The frequency, nature of injury (new or recurrent), onset (sudden or gradual), cause, location and exercise/treatment outcome were recorded. RESULTS Eleven per cent (n=136 cases) of the deployed population (n=1179) reported a musculoskeletal injury, which were mainly 'new' (62%), and with a 'sudden' onset (64%). Injury rate was 17.8 injuries per 10 000 personnel days. The majority of injuries occurred due to military training (88%), specifically during ski-related (61%) and load carriage (10%) activities.The average Service Person treated by the Forward Rehabilitation Team improved from 'injured with restricted duties' to 'fully fit', and with an improvement in their self-reported Musculoskeletal Health Questionnaire from 33 to 45 over an average of two rehabilitation sessions. One hundred and seventeen Service Personnel were able to continue on Ex CETUS with rehabilitation in theatre, thus negating the requirement for aeromedical evacuation for continuation of rehabilitation in the UK. Nineteen patients were unable to continue their Cold Weather Deployment due to the nature of their musculoskeletal injury and returned to the UK for continued care in firm base rehabilitation centres. CONCLUSION This study identifies the nature, causation and injury location. It demonstrates the effectiveness of in-theatre rehabilitation and the ability to treat patients when deployed. Recommendations are presented to support strategies to mitigate musculoskeletal injury risk during future Cold Weather Warfare deployments to Norway.
Collapse
Affiliation(s)
| | - D Hayhurst
- Rehab Div, DMRC Headley Court, Epsom, UK
| | - R Strachan
- Aviation Medicine Training Wing, Centre of Aviation Medicine, RAF Henlow, Bedfordshire, UK
| | - H Knapman
- PCRF, Medical Reception Station, Medical Centre, Dhekelia, UK
| | - S Wood
- HDIS, Specialist Group Military Intelligence (SGMI), Hermitage, Berkshire, UK
| | - J L Fallowfield
- Environmental Medicine and Science Division, Institute of Naval Medicine, Alverstoke, Hampshire, UK
| |
Collapse
|
5
|
Saha S, Boesch C, Maycock J, Wood S, Do T. Sweet Orange Juice Processing By-Product Extracts: A Caries Management Alternative to Chlorhexidine. Biomolecules 2023; 13:1607. [PMID: 38002290 PMCID: PMC10669069 DOI: 10.3390/biom13111607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Revised: 10/27/2023] [Accepted: 10/31/2023] [Indexed: 11/26/2023] Open
Abstract
Dental caries is one of the most prevalent chronic diseases globally in both children and adults. This study investigated the potential of industrial sweet orange waste extracts (ISOWE) as a substitute for chlorhexidine (CHX) in managing dental caries. First, the cytotoxicity of ISOWE (40, 80, 120 mg/mL) and CHX (0.1 and 0.2%) on buccal epithelial cells was determined. ISOWE exhibited no overall toxicity, whereas CHX strongly affected cell viability. The combination of ISOWE and CHX significantly enhanced cell proliferation compared to CHX alone. Next, the antimicrobial efficacy of ISOWE, CHX, and their combination was assessed against a 7-day complex biofilm model inoculated with oral samples from human volunteers. CHX exhibited indiscriminate antimicrobial action, affecting both pathogenic and health-associated oral microorganisms. ISOWE demonstrated lower antimicrobial efficacy than CHX but showed enhanced efficacy against pathogenic species while preserving the oral microbiome's balance. When applied to a cariogenic biofilm, the combined treatment of ISOWE with 0.1% CHX showed similar efficacy to 0.2% CHX treatment alone. Overall, the findings suggest that ISOWE is a promising natural anti-cariogenic agent with lower toxicity and enhanced selectivity for pathogenic species compared to CHX.
Collapse
Affiliation(s)
- Suvro Saha
- School of Food Science and Nutrition, Faculty of Environment, University of Leeds, Leeds LS2 9JT, UK; (S.S.)
- School of Dentistry, Division of Oral Biology, Faculty of Medicine & Health, University of Leeds, Leeds LS9 7TF, UK
| | - Christine Boesch
- School of Food Science and Nutrition, Faculty of Environment, University of Leeds, Leeds LS2 9JT, UK; (S.S.)
| | - Joanne Maycock
- School of Food Science and Nutrition, Faculty of Environment, University of Leeds, Leeds LS2 9JT, UK; (S.S.)
| | - Simon Wood
- School of Dentistry, Division of Oral Biology, Faculty of Medicine & Health, University of Leeds, Leeds LS9 7TF, UK
| | - Thuy Do
- School of Dentistry, Division of Oral Biology, Faculty of Medicine & Health, University of Leeds, Leeds LS9 7TF, UK
| |
Collapse
|
6
|
Solnier J, Zhang Y, Kuo YC, Du M, Roh K, Gahler R, Wood S, Chang C. Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers. Pharmaceutics 2023; 15:2567. [PMID: 38004546 PMCID: PMC10675484 DOI: 10.3390/pharmaceutics15112567] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 10/20/2023] [Accepted: 10/25/2023] [Indexed: 11/26/2023] Open
Abstract
Berberine is a plant-origin quaternary isoquinoline alkaloid with a vast array of biological activities, including antioxidant and blood-glucose- and blood-lipid-lowering effects. However, its therapeutic potential is largely limited by its poor oral bioavailability. The aim of this study was to investigate the in vitro solubility and Caco-2 cell permeability followed by pharmacokinetic profiling in healthy volunteers of a new food-grade berberine delivery system (i.e., Berberine LipoMicel®). X-ray diffractometry (XRD), in vitro solubility, and Caco-2 cell permeability indicated higher bioavailability of LipoMicel Berberine (LMB) compared to the standard formulation. Increased aqueous solubility (up to 1.4-fold), as well as improved Caco-2 cell permeability of LMB (7.18 × 10-5 ± 7.89 × 10-6 cm/s), were observed when compared to standard/unformulated berberine (4.93 × 10-6 ± 4.28 × 10-7 cm/s). Demonstrating better uptake, LMB achieved significant increases in AUC0-24 and Cmax compared to the standard formulation (AUC: 78.2 ± 14.4 ng h/mL vs. 13.4 ± 1.97 ng h/mL, respectively; p < 0.05; Cmax: 15.8 ± 2.6 ng/mL vs. 1.67 ± 0.41 ng/mL) in a pilot study of healthy volunteers (n = 10). No adverse reactions were reported during the study period. In conclusion, LMB presents a highly bioavailable formula with superior absorption (up to six-fold) compared to standard berberine formulation and may, therefore, have the potential to improve the therapeutic efficacy of berberine. The study has been registered on ClinicalTrials.gov with Identifier NCT05370261.
Collapse
Affiliation(s)
- Julia Solnier
- ISURA, Burnaby, BC V3N 4S9, Canada; (Y.Z.); (Y.C.K.); (M.D.); (K.R.); (C.C.)
| | - Yiming Zhang
- ISURA, Burnaby, BC V3N 4S9, Canada; (Y.Z.); (Y.C.K.); (M.D.); (K.R.); (C.C.)
| | - Yun Chai Kuo
- ISURA, Burnaby, BC V3N 4S9, Canada; (Y.Z.); (Y.C.K.); (M.D.); (K.R.); (C.C.)
| | - Min Du
- ISURA, Burnaby, BC V3N 4S9, Canada; (Y.Z.); (Y.C.K.); (M.D.); (K.R.); (C.C.)
| | - Kyle Roh
- ISURA, Burnaby, BC V3N 4S9, Canada; (Y.Z.); (Y.C.K.); (M.D.); (K.R.); (C.C.)
| | | | - Simon Wood
- School of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA 6845, Australia;
- InovoBiologic Inc., Calgary, AB Y2N 4Y7, Canada
- Food, Nutrition and Health Program, University of British Columbia, Vancouver, BC V6T 1Z4, Canada
| | - Chuck Chang
- ISURA, Burnaby, BC V3N 4S9, Canada; (Y.Z.); (Y.C.K.); (M.D.); (K.R.); (C.C.)
| |
Collapse
|
7
|
Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste B, Davey R, Ruben J, Foroudi F, Higgs BG, Lin C, Raman A, Hardcastle N, Shaw M, Mancuso P, Lawrentschuk N, Wood S, Brook N, Kron T, Martin JM, Pryor DI. TROG 15.03/ANZUP International Multicenter Phase II Trial of Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II). Int J Radiat Oncol Biol Phys 2023; 117:S3. [PMID: 37784470 DOI: 10.1016/j.ijrobp.2023.06.208] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Stereotactic body radiotherapy (SBRT) is an emerging non-invasive alternative for primary renal cell cancer (RCC) in patients unsuitable for surgery. The objective of the FASTRACK II clinical trial was to investigate the efficacy of SBRT for primary RCC. MATERIALS/METHODS This non-randomized, intergroup multi-institutional phase II study was activated in 7 Australian centers and 1 Dutch center, through the Trans Tasman Radiation Oncology Group (TROG) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Eligible patients had biopsy confirmed diagnosis of primary RCC with a single lesion within a kidney, ECOG performance ≤2 and were medically inoperable, high risk or declined surgery. For tumors ≤4 cm a single fraction of 26 Gy was prescribed, for tumors > 4 cm, 42 Gy in three fractions was prescribed. The primary outcome of the study was to estimate the efficacy of SBRT for primary RCC, defined as local control based on RECIST criteria. The study was powered assuming that 1-year local control would be 90%, with the null hypothesis of ≤80% considered undesirable and not worthy of proceeding to a future randomized controlled trial. RESULTS Between July 2016 and February 2020, 70 patients were enrolled with a median follow-up of 42 months. Median age was 77 years. Forty-nine patients were male (70%), median BMI was 32 and median Charlson comorbidity score was 7. The median [IQR] RENAL complexity score was 8 [7-10]. Biopsy confirmation was 100%. Twenty-three patients (33%) had T1a disease. The median (interquartile range [IQR]) tumor size was 4.6cm [3.7-5.5]; it was 3.3cm [3.0-3.6] in those receiving single fraction (n = 23), and 5.3cm [4.6-6.0] in those receiving 3-fraction SBRT (n = 47). During real-time pre-treatment quality assurance review, 10 cases (14.3%) required resubmission for protocol deviation, 2119 variables were assessed at final review, and final protocol compliance was 99.3%. Seven (10%) patients experienced grade 3 treatment-related adverse events, with no grade 4 or 5 events observed. Eleven (16%) patients reported no adverse events. Local control was 100% throughout the lifetime of the trial (p<0.001). Cancer-specific survival was also 100% throughout the lifetime of the trial. Freedom from distant failure (95% CIs) at 1 and 3 years was 99% (90-100%). Overall survival (95% CIs) at 1 and 3 years was 99% (90-100%) and 82% (70-89%), respectively. Baseline mean eGFR (95% CI) was 61.1 mLs/min (56.6; 65.6) and reduced by -10.8 mLs/min (-13.0; -8.6) by 1-year, by -14.6 mLs/min (-17.0; -12.2) by 2-years and plateaued thereafter. CONCLUSION In the first multicenter prospective trial of a non-surgical primary RCC cohort, enrolling mostly T1b+ disease, SBRT was an effective treatment strategy with no observed local failures. We observed an acceptable side effect profile and renal function after SBRT. These outcomes support the design of a future randomized clinical trial of SBRT versus surgery for primary RCC. The trial was registered with ID: NCT02613819.
Collapse
Affiliation(s)
- S Siva
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - M Bressel
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
| | - M Sidhom
- Liverpool Hospital Cancer Therapy Centre, University of New South Wales, School of Medicine, Sydney, NSW, Australia
| | - S Sridharan
- Calvary Mater Newcastle, Waratah & School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia
| | - B Vanneste
- Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands
| | - R Davey
- TROG Cancer Research, Waratah, NSW, Australia
| | - J Ruben
- The William Buckland Radiotherapy Centre, Alfred Health, Melbourne, VIC, Australia
| | - F Foroudi
- Austin Health, Radiation Oncology, Melbourne, Australia
| | - B G Higgs
- Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - C Lin
- Dept of Radiation Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
| | - A Raman
- Royal Newcastle Centre, John Hunter Hospital & School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - N Hardcastle
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
| | - M Shaw
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - P Mancuso
- Urology Department, Liverpool Hospital, Sydney, NSW, Australia
| | - N Lawrentschuk
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - S Wood
- Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - N Brook
- Department of Surgery, School of Medicine, University of Adelaide, Adelaide, SA, Australia
| | - T Kron
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
| | - J M Martin
- Department of Radiation Oncology, Calvary Mater Newcastle & School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - D I Pryor
- Princess Alexandra Hospital, Brisbane, QLD, Australia
| |
Collapse
|
8
|
Wijesooriya K, Larner JM, Read PW, Showalter TN, Lum L, Conaway M, Nguyen C, Lain D, Thakur A, Romano K, McLaughlin C, Jr EMJ, Luminais C, Wood S, Cousins DF, Chen J, Muller DA, Dutta SW, Nesbit EA, Ward KA, Sanders J, Chavis Y, Asare E. Initial Report of a Randomized Trial Comparing Conventional vs. Novel Treatment Planning Technique to Ameliorate Immunosuppression from Lung SBRT. Int J Radiat Oncol Biol Phys 2023; 117:e73-e74. [PMID: 37786124 DOI: 10.1016/j.ijrobp.2023.06.809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) SBRT is highly effective against early-stage non-small cell lung cancer. Radiation Therapy (RT) is known to modulate the immune system and contribute to the generation of anti-tumor T cells and stimulate T cell infiltration into tumors. However, this anti-tumor activity is offset by radiation-induced immunosuppression (RIIS) which results in lower tumor control and survival. Lymphocytes are highly radiosensitive and RIIS means destroying existing as well as newly created cytotoxic and helper T lymphocytes. We hypothesized that optimizing RT treatment planning by considering circulating blood and lymphatics as a critical Organ at Risk (OAR) may mitigate RIIS. MATERIALS/METHODS We conducted an IRB approved NCI funded clinical trial for 50 early-stage lung cancer patients treated with SBRT alone, from 2020 to 2023, to investigate the ability to reduce RIIS by reducing dose to circulating blood and lymphatics with the aid of a predictive algorithm. All SBRT plans adhered to treatment parameters from RTOG 0813 (central) or RTOG 0915 (peripheral). Patients were randomized to two arms: experimental optimization for RIIS (to reduce dose to blood and lymphatic rich organs) versus standard SBRT planning (without optimization for RIIS). Peripheral blood samples were collected at baseline, end of Tx, 4 weeks and 6 months post Tx. Patients with baseline absolute lymphocyte counts (ALC) less than 0.5x109 cells/L were ineligible for the trial. Data acquired for all blood cell types as well as lymphocyte sub populations CD3+, CD4+, CD8+, CD19+, CD56+. Two sample t-test was used to determine the statistical significance between the cohorts at the time points. RESULTS The standard arm had an ALC reduction of 28% at one week post Tx and a nadir at 4 weeks with a 34% reduction. Absolute percentage reductions in ALC from baseline in the optimized arm compared to the standard arm are: end of treatment point (13%, p = 0.03), 4 weeks (12%, p = 0.08), 6 months (15%, p = 0.1), and all three time points together 13% (p = 0.001). ALC recovery appears to be faster in the optimized arm. Radiation induced suppression of all blood cell types are also reduced in the optimized arm with respect to standard arm (relative percentages): ALC (34%), WBC (47%), RBC (46%), platelets (40%), monocytes (100%), and neutrophils (62%) at 4-week mark. Average percentage reductions on integral doses, and V5 (volume receiving a 5 Gy dose) of optimized compared to standard plans are: aorta: 26%, 41% heart: 8%, 33%, vena cava: 32%, 52%, T spine: 51%, 81%, lymph nodes: 35%, 57%, total lung- ITV: 1.6%, 1%, body: 10%, 14%. CONCLUSION For the first time, we have shown that it is possible to reduce RIIS in a statistically significant manner, compared to standard of care, via optimized RT planning using a predictive model. This has implications in increasing the efficacy of immunotherapy by preserving the existing tumor reactive T cells in the immune system to enhance anti-tumor activity, and in reducing hospitalizations and improving survival.
Collapse
Affiliation(s)
- K Wijesooriya
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - J M Larner
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - P W Read
- University of Virginia, Charlottesville, VA
| | - T N Showalter
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA; University of Virginia, Charlottesville, VA
| | - L Lum
- University of Virginia, Charlottesville, VA
| | - M Conaway
- University of Virginia, Charlottesville, VA
| | - C Nguyen
- University of Virginia, Charlottesville, VA
| | - D Lain
- University of Virginia, Charlottesville, VA, United States
| | - A Thakur
- University of Virginia, Charlottesville, VA
| | - K Romano
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - C McLaughlin
- University of Virginia, Department of Radiation Oncology, Charlottesville, VA
| | - E M Janowski Jr
- University of Virginia Department of Radiation Oncology, Charlottesville, VA
| | - C Luminais
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - S Wood
- University of Virginia, Charlottesville, VA
| | - D F Cousins
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - J Chen
- University of Virginia, Charlottesville, VA
| | - D A Muller
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - S W Dutta
- Department of Radiation Oncology, Emory University, Atlanta, GA
| | - E A Nesbit
- University of Virginia Department of Radiation Oncology, Charlottesville, VA
| | - K A Ward
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - J Sanders
- University of Virginia Department of Radiation Oncology, Charlottesville, VA
| | - Y Chavis
- University of Virginia Health Systems, Charlottesville, VA, United States
| | - E Asare
- University of Virginia Department of Radiation Oncology, Charlottesville, VA
| |
Collapse
|
9
|
Raghubar AM, Matigian NA, Crawford J, Francis L, Ellis R, Healy HG, Kassianos AJ, Ng MSY, Roberts MJ, Wood S, Mallett AJ. High risk clear cell renal cell carcinoma microenvironments contain protumour immunophenotypes lacking specific immune checkpoints. NPJ Precis Oncol 2023; 7:88. [PMID: 37696903 PMCID: PMC10495390 DOI: 10.1038/s41698-023-00441-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2023] [Accepted: 08/30/2023] [Indexed: 09/13/2023] Open
Abstract
Perioperative immune checkpoint inhibitor (ICI) trials for intermediate high-risk clear cell renal cell carcinoma (ccRCC) have failed to consistently demonstrate improved patient outcomes. These unsuccessful ICI trials suggest that the tumour infiltrating immunophenotypes, termed here as the immune cell types, states and their spatial location within the tumour microenvironment (TME), were unfavourable for ICI treatment. Defining the tumour infiltrating immune cells may assist with the identification of predictive immunophenotypes within the TME that are favourable for ICI treatment. To define the immunophenotypes within the ccRCC TME, fresh para-tumour (pTME, n = 2), low-grade (LG, n = 4, G1-G2) and high-grade (HG, n = 4, G3-G4) tissue samples from six patients with ccRCC presenting at a tertiary referral hospital underwent spatial transcriptomics sequencing (ST-seq). Within the generated ST-seq datasets, immune cell types and states, termed here as exhausted/pro-tumour state or non-exhausted/anti-tumour state, were identified using multiple publicly available single-cell RNA and T-cell receptor sequencing datasets as references. HG TMEs revealed abundant exhausted/pro-tumour immune cells with no consistent increase in expression of PD-1, PD-L1 and CTLA4 checkpoints and angiogenic genes. Additional HG TME immunophenotype characteristics included: pro-tumour tissue-resident monocytes with consistently increased expression of HAVCR2 and LAG3 checkpoints; an exhausted CD8+ T cells sub-population with stem-like progenitor gene expression; and pro-tumour tumour-associated macrophages and monocytes within the recurrent TME with the expression of TREM2. Whilst limited by a modest sample size, this study represents the largest ST-seq dataset on human ccRCC. Our study reveals that high-risk ccRCC TMEs are infiltrated by exhausted/pro-tumour immunophenotypes lacking specific checkpoint gene expression confirming that HG ccRCC TME are immunogenic but not ICI favourable.
Collapse
Affiliation(s)
- Arti M Raghubar
- Kidney Health Service, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
- Conjoint Internal Medicine Laboratory, Chemical Pathology, Pathology Queensland, Health Support Queensland, Herston, QLD, Australia
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
- Anatomical Pathology, Pathology Queensland, Health Support Queensland, Herston, QLD, Australia
- Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia
- Faculty of Health, Charles Darwin University, Darwin, NT, Australia
| | - Nicholas A Matigian
- QCIF Facility for Advanced Bioinformatics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia
| | - Joanna Crawford
- Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia
| | - Leo Francis
- Anatomical Pathology, Pathology Queensland, Health Support Queensland, Herston, QLD, Australia
| | - Robert Ellis
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
- Department of Urology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - Helen G Healy
- Kidney Health Service, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
- Conjoint Internal Medicine Laboratory, Chemical Pathology, Pathology Queensland, Health Support Queensland, Herston, QLD, Australia
| | - Andrew J Kassianos
- Kidney Health Service, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
- Conjoint Internal Medicine Laboratory, Chemical Pathology, Pathology Queensland, Health Support Queensland, Herston, QLD, Australia
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
| | - Monica S Y Ng
- Kidney Health Service, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
- Conjoint Internal Medicine Laboratory, Chemical Pathology, Pathology Queensland, Health Support Queensland, Herston, QLD, Australia
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
- Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia
- Nephrology Department, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
| | - Matthew J Roberts
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
- Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
- Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia
| | - Simon Wood
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
- Department of Urology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - Andrew J Mallett
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
- Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.
- College of Medicine & Dentistry, James Cook University, Townsville, QLD, Australia.
- Department of Renal Medicine, Townsville University Hospital, Townsville, QLD, Australia.
| |
Collapse
|
10
|
Solnier J, Zhang Y, Roh K, Kuo YC, Du M, Wood S, Hardy M, Gahler RJ, Chang C. A Pharmacokinetic Study of Different Quercetin Formulations in Healthy Participants: A Diet-Controlled, Crossover, Single- and Multiple-Dose Pilot Study. Evid Based Complement Alternat Med 2023; 2023:9727539. [PMID: 37600550 PMCID: PMC10435304 DOI: 10.1155/2023/9727539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 04/25/2023] [Accepted: 08/02/2023] [Indexed: 08/22/2023]
Abstract
This study aimed to evaluate the blood concentrations of quercetin in healthy participants after the administration of different formulations in single- and multiple-dose phases. Ten healthy adults (males, 5; females, 5; age 37 ± 11 years) participated in a diet-controlled, crossover pilot study. Participants received three different doses (250 mg, 500 mg, or 1000 mg) of quercetin aglycone orally. In the single-dose study, blood concentrations (AUC0-24 and Cmax) of standard quercetin were compared with those of LipoMicel®-a food-grade delivery form of quercetin. In the multiple-dose study, blood concentrations of formulated quercetin were observed over 72 h, after repeated doses of LipoMicel (LM) treatments. The AUC0-24 ranged from 77.3 to 1128.9 ng·h/ml: LM significantly increased blood concentrations of quercetin by 7-fold (LM 500) compared to standard quercetin, when tested at the same dose, over 24 h (p < 0.001); LM administered at a higher dose (LM 1000) achieved 15-fold higher absorption (p < 0.001); LM tested at half a dose of standard quercetin increased concentration by approx. 3-fold (LM 250). Quercetin blood concentrations were attained over 72 h. The major metabolites measured in the blood were methylated, sulfate, and glutathione (GSH) conjugates of quercetin. Significant differences in concentrations between quercetin conjugates (sulfate vs. methyl vs. GSH) were observed (p < 0.001). Data obtained from this study suggest that supplementation with LipoMicel® is a promising strategy to increase the absorption of quercetin and its health-promoting effects in humans. However, due to the low sample size in this pilot study, further research is still warranted to confirm the observations in larger populations. This trial is registered with NCT05611827.
Collapse
Affiliation(s)
| | | | - Kyle Roh
- ISURA, Burnaby, BC V3N4S9, Canada
| | | | - Min Du
- ISURA, Burnaby, BC V3N4S9, Canada
| | - Simon Wood
- School of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA 6845, Australia
- InovoBiologic Inc., Calgary, AB Y2N4Y7, Canada
- Food, Nutrition and Health Program, University of British Columbia, Vancouver, BC V6T1Z4, Canada
| | - Mary Hardy
- Association of Integrative and Holistic Medicine, San Diego, California, USA
| | | | | |
Collapse
|
11
|
Ali M, Wood S, Pryor D, Moon D, Bressel M, Azad AA, Mitchell C, Murphy D, Zargar H, Hardcastle N, Kearsley J, Eapen R, Wong LM, Cuff K, Lawrentschuk N, Neeson PJ, Siva S. NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial. Contemp Clin Trials Commun 2023; 33:101145. [PMID: 37168818 PMCID: PMC10164766 DOI: 10.1016/j.conctc.2023.101145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Revised: 04/13/2023] [Accepted: 04/21/2023] [Indexed: 05/13/2023] Open
Abstract
Background Surgery remains the standard of care for localised renal cell carcinoma (RCC). Nevertheless, nearly 50% of patients with high-risk disease experience relapse after surgery, with distant sites being common. Considering improved outcomes in terms of disease-free survival with adjuvant immunotherapy with pembrolizumab, we hypothesise that neoadjuvant SABR with or without the addition of pembrolizumab before nephrectomy will lead to improved disease outcomes by evoking better immune response in the presence of an extensive reserve of tumor-associated antigens. Methods and analysis This prospective, open-label, phase II, randomised, non-comparative, clinical trial will investigate the use of neoadjuvant stereotactic ablative body radiotherapy (SABR) with or without pembrolizumab prior to nephrectomy. The trial will be conducted at two centres in Australia that are well established for delivering SABR to primary RCC patients. Twenty-six patients with biopsy-proven clear cell RCC will be recruited over two years. Patients will be randomised to either SABR or SABR/pembrolizumab. Patients in both arms will undergo surgery at 9 weeks after completion of experimental treatment. The primary objectives are to describe major pathological response and changes in tumour-responsive T-cells from baseline pre-treatment biopsy in each arm. Patients will be followed for sixty days post-surgery. Outcomes and significance We hypothesize that SABR alone or SABR plus pembrolizumab will induce significant tumor-specific immune response and major pathological response. In that case, either one or both arms could justifiably be used as a neoadjuvant treatment approach in future randomized trials in the high-risk patient population.
Collapse
Affiliation(s)
- Muhammad Ali
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia
- Corresponding author. 305 Grattan Street, Melbourne, Victoria, 3000, Australia.
| | - Simon Wood
- Metro South Hospital and Health Service, Brisbane, QLD, Australia
- Department of Urology, Princess Alexandra Hospital, Brisbane, QLD, Australia
- Centre for Kidney Disease Research, Translational Research Institute, Brisbane, QLD, Australia
| | - David Pryor
- Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia
- Queensland University of Technology, Brisbane, QLD, Australia
| | - Daniel Moon
- Deapartment of Surgery, The University of Melbourne, Melbourne, VIC, Australia
| | - Mathias Bressel
- Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Arun A. Azad
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Catherine Mitchell
- Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Declan Murphy
- Department of Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Homi Zargar
- Deapartment of Surgery, The University of Melbourne, Melbourne, VIC, Australia
| | - Nick Hardcastle
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia
- Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Centre for Medical Radiation Physics, University of Wollongong, NSW, Australia
| | - Jamie Kearsley
- Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia
| | - Renu Eapen
- Department of Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Lih Ming Wong
- Deapartment of Surgery, The University of Melbourne, Melbourne, VIC, Australia
- Department of Urology, St Vincent's Health, Melbourne, VIC, Australia
| | - Katharine Cuff
- Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - Nathan Lawrentschuk
- Deapartment of Surgery, The University of Melbourne, Melbourne, VIC, Australia
- Department of Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia
| | - Paul J. Neeson
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Shankar Siva
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia
| |
Collapse
|
12
|
Melo P, Wood S, Petsas G, Chung Y, Gorodeckaja J, Price MJ, Coomarasamy A. Reply to: 'Hiding in plain sight' and 'Caution is needed when communicating analyses based on an apple to orange comparison'. Hum Reprod Open 2023; 2023:hoad017. [PMID: 37273768 PMCID: PMC10234702 DOI: 10.1093/hropen/hoad017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023] Open
Affiliation(s)
- Pedro Melo
- Correspondence address. Tommy’s National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston B15 277, UK. E-mail:
| | | | | | - Yealin Chung
- Tommy’s National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, UK
- CARE Fertility Birmingham, Edgbaston, UK
| | | | - Malcolm J Price
- Institute of Applied Health Research, University of Birmingham, Edgbaston, UK
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
| | - Arri Coomarasamy
- Tommy’s National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, UK
- CARE Fertility Birmingham, Edgbaston, UK
| |
Collapse
|
13
|
Best KP, Gould JF, Makrides M, Sullivan T, Cheong J, Zhou SJ, Kane S, Safa H, Sparks A, Doyle LW, McPhee AJ, Nippita TAC, Afzali HHA, Grivell R, Mackerras D, Knight E, Wood S, Green T. Prenatal iodine supplementation and early childhood neurodevelopment: the PoppiE trial - study protocol for a multicentre randomised controlled trial. BMJ Open 2023; 13:e071359. [PMID: 37164467 PMCID: PMC10173960 DOI: 10.1136/bmjopen-2022-071359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/12/2023] Open
Abstract
INTRODUCTION Observational studies suggest both low and high iodine intakes in pregnancy are associated with poorer neurodevelopmental outcomes in children. This raises concern that current universal iodine supplement recommendations for pregnant women in populations considered to be iodine sufficient may negatively impact child neurodevelopment. We aim to determine the effect of reducing iodine intake from supplements for women who have adequate iodine intake from food on the cognitive development of children at 24 months of age. METHODS AND ANALYSIS A multicentre, randomised, controlled, clinician, researcher and participant blinded trial with two parallel groups. Using a hybrid decentralised clinical trial model, 754 women (377 per group) less than 13 weeks' gestation with an iodine intake of ≥165 µg/day from food will be randomised to receive either a low iodine (20 µg/day) multivitamin and mineral supplement or an identical supplement containing 200) µg/day (amount commonly used in prenatal supplements in Australia), from enrolment until delivery. The primary outcome is the developmental quotient of infants at 24 months of age assessed with the Cognitive Scale of the Bayley Scales of Infant Development, fourth edition. Secondary outcomes include infant language and motor development; behavioural and emotional development; maternal and infant clinical outcomes and health service utilisation of children. Cognitive scores will be compared between groups using linear regression, with adjustment for location of enrolment and the treatment effect described as a mean difference with 95% CI. ETHICS AND DISSEMINATION Ethical approval has been granted from the Women's and Children's Health Network Research Ethics Committee (HREC/17/WCHN/187). The results of this trial will be presented at scientific conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT04586348.
Collapse
Affiliation(s)
- Karen P Best
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
| | - Jacqueline F Gould
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
| | - Maria Makrides
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
| | - Thomas Sullivan
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- School of Public Health, The University of Adelaide, Adelaide, South Australia, Australia
| | - Jeanie Cheong
- Newborn Services, Royal Women's Hospital, Parkville, Victoria, Australia
- Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia
| | - Shao J Zhou
- School of Agriculture, Food & Wine, The University of Adelaide, Adelaide, South Australia, Australia
| | - Stefan Kane
- Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia
- Department of Maternal Fetal Medicine, Royal Women's Hospital, Parkville, Victoria, Australia
| | - Huda Safa
- School of Medicine, University of Queensland, Brisbane, Queensland, Australia
- Department of Obstetrics and Gynaecology, Mater Mothers' Hospital, Brisbane, Queensland, Australia
| | - A Sparks
- Department of Neonatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
| | - Lex W Doyle
- Department of Maternal Fetal Medicine, Royal Women's Hospital, Parkville, Victoria, Australia
- Obstetrics and Gynaecology, Royal Women's Hospital, Parkville, Victoria, Australia
| | - A J McPhee
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
| | - Tanya A C Nippita
- Women and Babies, Kolling Institute of Medical Research, St Leonards, New South Wales, Australia
- Northern Clinical School, The University of Sydney, Sydney, New South Wales, Australia
| | - Hossein H A Afzali
- College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
| | - Rosalie Grivell
- Department of Obstetrics and Gynaecology, Flinders University, Adelaide, South Australia, Australia
| | - D Mackerras
- Menzies School of Health Research, Casuarina, Northern Territory, Australia
| | - E Knight
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- School of Public Health, The University of Adelaide, Adelaide, South Australia, Australia
| | - Simon Wood
- Faculty of Land and Food Systems, University of British Columbia, Victoria, British Columbia, Canada
- Faculty of Science and Engineering, Curtin University, Perth, Western Australia, Australia
| | - Tim Green
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
| |
Collapse
|
14
|
Saha S, Do T, Maycock J, Wood S, Boesch C. Antibiofilm Efficacies of Flavonoid-Rich Sweet Orange Waste Extract against Dual-Species Biofilms. Pathogens 2023; 12:pathogens12050657. [PMID: 37242327 DOI: 10.3390/pathogens12050657] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 04/21/2023] [Accepted: 04/24/2023] [Indexed: 05/28/2023] Open
Abstract
The current study evaluated the antibacterial properties of industrial sweet orange waste extracts (ISOWEs), which are a rich source of flavonoids. The ISOWEs exhibited antibacterial activity towards the dental cariogenic pathogens Streptococcus mutans and Lactobacillus casei with 13.0 ± 2.0 and 20.0 ± 2.0 mg/mL for MIC (minimum inhibitory concentration) and 37.7 ± 1.5 and 43.3 ± 2.1 mg/mL for MBC (minimum bactericidal concentration), respectively. When evaluated in a 7-day dual-species oral biofilm model, ISOWEs dose-dependently reduced the viable bacteria count, and demonstrated strong synergistic effects when combined with the anti-septic chlorhexidine (at 0.1 and 0.2%). Similarly, confocal microscopy confirmed the anti-cariogenic properties of ISOWEs, alone and in combination with chlorhexidine. The citrus flavonoids contributed differently to these effects, with the flavones (nobiletin, tangeretin and sinensetin) demonstrating significantly lower MICs and MBCs compared to the flavanones hesperidin and narirutin. In conclusion, our study demonstrated the potential of citrus waste as a currently underutilised source of flavonoids for antimicrobial applications, such as in dental health.
Collapse
Affiliation(s)
- Suvro Saha
- School of Food Science and Nutrition, Faculty of Environment, University of Leeds, Leeds LS2 9JT, UK
- School of Dentistry, Division of Oral Biology, Faculty of Medicine & Health, University of Leeds, Leeds LS2 9LU, UK
| | - Thuy Do
- School of Dentistry, Division of Oral Biology, Faculty of Medicine & Health, University of Leeds, Leeds LS2 9LU, UK
| | - Joanne Maycock
- School of Food Science and Nutrition, Faculty of Environment, University of Leeds, Leeds LS2 9JT, UK
| | - Simon Wood
- School of Dentistry, Division of Oral Biology, Faculty of Medicine & Health, University of Leeds, Leeds LS2 9LU, UK
| | - Christine Boesch
- School of Food Science and Nutrition, Faculty of Environment, University of Leeds, Leeds LS2 9JT, UK
| |
Collapse
|
15
|
Duran B, Meziani ZE, Joosten S, Jones MK, Prasad S, Peng C, Armstrong W, Atac H, Chudakov E, Bhatt H, Bhetuwal D, Boer M, Camsonne A, Chen JP, Dalton MM, Deokar N, Diefenthaler M, Dunne J, El Fassi L, Fuchey E, Gao H, Gaskell D, Hansen O, Hauenstein F, Higinbotham D, Jia S, Karki A, Keppel C, King P, Ko HS, Li X, Li R, Mack D, Malace S, McCaughan M, McClellan RE, Michaels R, Meekins D, Paolone M, Pentchev L, Pooser E, Puckett A, Radloff R, Rehfuss M, Reimer PE, Riordan S, Sawatzky B, Smith A, Sparveris N, Szumila-Vance H, Wood S, Xie J, Ye Z, Yero C, Zhao Z. Determining the gluonic gravitational form factors of the proton. Nature 2023; 615:813-816. [PMID: 36991189 DOI: 10.1038/s41586-023-05730-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Accepted: 01/13/2023] [Indexed: 03/31/2023]
Abstract
The proton is one of the main building blocks of all visible matter in the Universe1. Among its intrinsic properties are its electric charge, mass and spin2. These properties emerge from the complex dynamics of its fundamental constituents-quarks and gluons-described by the theory of quantum chromodynamics3-5. The electric charge and spin of protons, which are shared among the quarks, have been investigated previously using electron scattering2. An example is the highly precise measurement of the electric charge radius of the proton6. By contrast, little is known about the inner mass density of the proton, which is dominated by the energy carried by gluons. Gluons are hard to access using electron scattering because they do not carry an electromagnetic charge. Here we investigated the gravitational density of gluons using a small colour dipole, through the threshold photoproduction of the J/ψ particle. We determined the gluonic gravitational form factors of the proton7,8 from our measurement. We used a variety of models9-11 and determined, in all cases, a mass radius that is notably smaller than the electric charge radius. In some, but not all cases, depending on the model, the determined radius agrees well with first-principle predictions from lattice quantum chromodynamics12. This work paves the way for a deeper understanding of the salient role of gluons in providing gravitational mass to visible matter.
Collapse
Affiliation(s)
- B Duran
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - Z-E Meziani
- Physics Division, Argonne National Laboratory, Lemont, IL, USA.
- Department of Physics, Temple University, Philadelphia, PA, USA.
| | - S Joosten
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - M K Jones
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - S Prasad
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - C Peng
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - W Armstrong
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - H Atac
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - E Chudakov
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - H Bhatt
- Department of Physics & Astronomy, Mississippi State University, Mississippi State, MS, USA
| | - D Bhetuwal
- Department of Physics & Astronomy, Mississippi State University, Mississippi State, MS, USA
| | - M Boer
- Department of Physics, Virginia Polytechnic Institute & State University, Blacksburg, VA, USA
| | - A Camsonne
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - J-P Chen
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - M M Dalton
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - N Deokar
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - M Diefenthaler
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - J Dunne
- Department of Physics & Astronomy, Mississippi State University, Mississippi State, MS, USA
| | - L El Fassi
- Department of Physics & Astronomy, Mississippi State University, Mississippi State, MS, USA
| | - E Fuchey
- Department of Physics, University of Connecticut, Storrs, CT, USA
| | - H Gao
- Department of Physics, Duke University, Durham, NC, USA
| | - D Gaskell
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - O Hansen
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - F Hauenstein
- Department of Physics, Old Dominion University, Norfolk, VA, USA
| | - D Higinbotham
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - S Jia
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - A Karki
- Department of Physics & Astronomy, Mississippi State University, Mississippi State, MS, USA
| | - C Keppel
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - P King
- Department of Physics and Astronomy, Ohio University, Athens, OH, USA
| | - H S Ko
- CNRS/IN2P3, IJCLab Orsay, Université Paris-Saclay, Gif-sur-Yvette, France
| | - X Li
- Department of Physics, Duke University, Durham, NC, USA
| | - R Li
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - D Mack
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - S Malace
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - M McCaughan
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - R E McClellan
- Natural Sciences Department, Pensacola State College, Pensacola, FL, USA
| | - R Michaels
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - D Meekins
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - Michael Paolone
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - L Pentchev
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - E Pooser
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - A Puckett
- Department of Physics, University of Connecticut, Storrs, CT, USA
| | - R Radloff
- Department of Physics and Astronomy, Ohio University, Athens, OH, USA
| | - M Rehfuss
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - S Riordan
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - B Sawatzky
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - A Smith
- Department of Physics, Duke University, Durham, NC, USA
| | - N Sparveris
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - H Szumila-Vance
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - S Wood
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - J Xie
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - Z Ye
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - C Yero
- Department of Physics, Old Dominion University, Norfolk, VA, USA
| | - Z Zhao
- Department of Physics, Duke University, Durham, NC, USA
| |
Collapse
|
16
|
Green T, See J, Schauch M, Reil J, Glover M, Brix J, Gerry A, Li K, Newman M, Gahler RJ, Wood S. A randomized, double-blind, placebo-controlled, cross-over trial to evaluate the effect of EstroSense ® on 2-hydroxyestrone:16α-hydroxyestrone ratio in premenopausal women. J Complement Integr Med 2023; 20:199-206. [PMID: 36201753 DOI: 10.1515/jcim-2022-0301] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Accepted: 09/14/2022] [Indexed: 06/16/2023]
Abstract
OBJECTIVES Some estrogen metabolites are associated with increased breast cancer risk, while others are protective. Research efforts have focused on modifiable factors, including bioactive compounds found in food or supplements, promoting estrogen profiles with anti-cancer properties. EstroSense® is a nutraceutical product with bioactive compounds, including Indole-3-carbinol and green-tea catechins, which may favourably affect estrogen profiles. This study was conducted to determine if EstroSense use, compared to placebo, promotes a higher urinary 2-hydroxyestrone:16α-hydroxyestrone ratio (2-OHE1:16α-OHE1), a biomarker associated with a lowered risk of breast cancer. METHODS A total of 148 premenopausal women were recruited from British Columbia, Canada to participate in a randomized, double-blind, cross-over, multicentre, placebo-controlled study in which women were randomized to a treatment sequence that consisted of either EstroSense®, followed by placebo or vice-versa. The women were instructed to consume three capsules per day of EstroSense® or the placebo for three menstrual cycles (∼12 weeks). The primary outcome was the measurement of 2-OHE1:16α-OHE1 in casual samples at baseline and after each treatment phase. RESULTS After 12 weeks of intervention, the mean (95% CI) urinary 2-OHE1:16α-OHE1 was 4.55 (2.69, 6.42) (p<0.001) higher following EstroSense than placebo adjusted for baseline values. CONCLUSIONS EstroSense use led to markedly higher urinary 2-OHE1:16α-OHE1 than the placebo, a biomarker associated with a lower risk of breast cancer. REGISTRATION http://clinicaltrials.gov (NCT02385916).
Collapse
Affiliation(s)
- Tim Green
- Adjunct Professor, Food, Nutrition and Health, University of British Columbia, Vancouver, BC, Canada
| | | | - Marita Schauch
- Tall Tree Integrated Health Centre, Victoria, BC, Canada
| | - Julie Reil
- Shiloh Medical Clinic, Billings, MT, USA
| | - Melissa Glover
- Tall Tree Integrated Health Centre, Victoria, BC, Canada
| | - Jennifer Brix
- Brix Family Chiropractic & Wellness Centre, Kelowna, BC, Canada
| | | | - Kathy Li
- Department of Paediatrics, University of British Columbia, Vancouver, BC, Canada
| | - Mark Newman
- Precision Analytical Inc., McMinnville, OR, USA
| | - Roland J Gahler
- Factors Group of Nutritional Products Inc. Research & Development, Burnaby, BC, Canada
| | - Simon Wood
- Adjunct Professor, Food, Nutrition and Health, University of British Columbia, Vancouver, BC, Canada
- School of Public Health, Faculty of Health Sciences, Curtin University, WA, Australia
| |
Collapse
|
17
|
Melo P, Wood S, Petsas G, Chung Y, Easter C, Price MJ, Fishel S, Khairy M, Kingsland C, Lowe P, Rajkhowa M, Sephton V, Pandey S, Kazem R, Walker D, Gorodeckaja J, Wilcox M, Gallos I, Tozer A, Coomarasamy A. The effect of frozen embryo transfer regimen on the association between serum progesterone and live birth: a multicentre prospective cohort study (ProFET). Hum Reprod Open 2022; 2022:hoac054. [PMID: 36518987 PMCID: PMC9733530 DOI: 10.1093/hropen/hoac054] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2022] [Revised: 11/16/2022] [Indexed: 08/03/2023] Open
Abstract
STUDY QUESTION What is the association between serum progesterone levels on the day of frozen embryo transfer (FET) and the probability of live birth in women undergoing different FET regimens? SUMMARY ANSWER Overall, serum progesterone levels <7.8 ng/ml were associated with reduced odds of live birth, although the association between serum progesterone levels and the probability of live birth appeared to vary according to the route of progesterone administration. WHAT IS KNOWN ALREADY Progesterone is essential for pregnancy success. A recent systematic review showed that in FET cycles using vaginal progesterone for endometrial preparation, lower serum progesterone levels (<10 ng/ml) were associated with a reduction in live birth rates and higher chance of miscarriage. However, there was uncertainty about the association between serum progesterone levels and treatment outcomes in natural cycle FET (NC-FET) and HRT-FET using non-vaginal routes of progesterone administration. STUDY DESIGN SIZE DURATION This was a multicentre (n = 8) prospective cohort study conducted in the UK between January 2020 and February 2021. PARTICIPANTS/MATERIALS SETTING METHODS We included women having NC-FET or HRT-FET treatment with progesterone administration by any available route. Women underwent venepuncture on the day of embryo transfer. Participants and clinical personnel were blinded to the serum progesterone levels. We conducted unadjusted and multivariable logistic regression analyses to investigate the association between serum progesterone levels on the day of FET and treatment outcomes according to the type of cycle and route of exogenous progesterone administration. Our primary outcome was the live birth rate per participant. MAIN RESULTS AND THE ROLE OF CHANCE We studied a total of 402 women. The mean (SD) serum progesterone level was 14.9 (7.5) ng/ml. Overall, the mean adjusted probability of live birth increased non-linearly from 37.6% (95% CI 26.3-48.9%) to 45.5% (95% CI 32.1-58.9%) as serum progesterone rose between the 10th (7.8 ng/ml) and 90th (24.0 ng/ml) centiles. In comparison to participants whose serum progesterone level was ≥7.8 ng/ml, those with lower progesterone (<7.8 ng/ml, 10th centile) experienced fewer live births (28.2% versus 40.0%, adjusted odds ratio [aOR] 0.41, 95% CI 0.18-0.91, P = 0.028), lower odds of clinical pregnancy (30.8% versus 45.1%, aOR 0.36, 95% CI 0.16-0.79, P = 0.011) and a trend towards increased odds of miscarriage (42.1% versus 28.7%, aOR 2.58, 95% CI 0.88-7.62, P = 0.086). In women receiving vaginal progesterone, the mean adjusted probability of live birth increased as serum progesterone levels rose, whereas women having exclusively subcutaneous progesterone experienced a reduction in the mean probability of live birth as progesterone levels rose beyond 16.3 ng/ml. The combination of vaginal and subcutaneous routes appeared to exert little impact upon the mean probability of live birth in relation to serum progesterone levels. LIMITATIONS REASONS FOR CAUTION The final sample size was smaller than originally planned, although our study was adequately powered to confidently identify a difference in live birth between optimal and inadequate progesterone levels. Furthermore, our cohort did not include women receiving oral or rectal progestogens. WIDER IMPLICATIONS OF THE FINDINGS Our results corroborate existing evidence suggesting that lower serum progesterone levels hinder FET success. However, the relationship between serum progesterone and the probability of live birth appears to be non-linear in women receiving exclusively subcutaneous progesterone, suggesting that in this subgroup of women, high serum progesterone may also be detrimental to treatment success. STUDY FUNDING/COMPETING INTERESTS This work was supported by CARE Fertility and a doctoral research fellowship (awarded to P.M.) by the Tommy's Charity and the University of Birmingham. M.J.P. is supported by the NIHR Birmingham Biomedical Research Centre. S.F. is a minor shareholder of CARE Fertility but has no financial or other interest with progesterone testing or manufacturing companies. P.L. reports personal fees from Pharmasure, outside the submitted work. G.P. reports personal fees from Besins Healthcare, outside the submitted work. M.W. reports personal fees from Ferring Pharmaceuticals, outside the submitted work. The remaining authors have no conflict of interest to declare. TRIAL REGISTRATION NUMBER ClinicalTrials.gov: NCT04170517.
Collapse
Affiliation(s)
- Pedro Melo
- Correspondence address. Tommy’s National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston B15 277, UK. Tel: +44-121-371-8202; E-mail:
| | | | | | - Yealin Chung
- Tommy’s National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, UK
- CARE Fertility Birmingham, Edgbaston, UK
| | - Christina Easter
- Institute of Applied Health Research, University of Birmingham, Edgbaston, UK
| | - Malcolm J Price
- Institute of Applied Health Research, University of Birmingham, Edgbaston, UK
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK
| | - Simon Fishel
- CARE Fertility Nottingham, Nottingham, UK
- Liverpool John Moores University, School of Pharmacy and Biomolecular Sciences, Liverpool, UK
| | | | | | | | | | | | | | | | | | | | | | - Ioannis Gallos
- Tommy’s National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, UK
| | | | - Arri Coomarasamy
- Tommy’s National Centre for Miscarriage Research, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, UK
- CARE Fertility Birmingham, Edgbaston, UK
| |
Collapse
|
18
|
Nolan GS, Dunne JA, Lee AE, Wade RG, Kiely AL, Pritchard Jones RO, Gardiner MD, Abbassi O, Abdelaty M, Ahmed F, Ahmed R, Ali S, Allan A, Allen L, Anderson I, Bakir A, Berwick D, Sarala BBN, Bhat W, Bloom O, Bolton L, Brady N, Campbell E, Capitelli-McMahon H, Cassell O, Chalhoub X, Chalmers R, Chan J, Chu HO, Collin T, Cooper K, Curran TA, Cussons D, Daruwalla M, Dearden A, Delikonstantinou I, Dobbs T, Dunlop R, El-Muttardi N, Eleftheriadou A, Elamin SE, Eriksson S, Exton R, Fourie LR, Freethy A, Gardner E, Geh JL, Georgiou A, Georgiou M, Gilbert P, Gkorila A, Green D, Haeney J, Hamilton S, Harper F, Harrison C, Heinze Z, Hemington-Gorse S, Hever P, Hili S, Holmes W, Hughes W, Ibrahim N, Ismail A, Jallali N, James NK, Jemec B, Jica R, Kaur A, Kazzazi D, Khan M, Khan N, Khashaba H, Khera B, Khoury A, Kiely J, Kumar S, Patel PK, Kumbasar DE, Kundasamy P, Kyle D, Langridge B, Liu C, Lo M, Macdonald C, Anandan SM, Mahdi M, Mandal A, Manning A, Markeson D, Matteucci P, McClymont L, Mikhail M, Miller MC, Munro S, Musajee A, Nasrallah F, Ng L, Nicholas R, Nicola A, Nikkhah D, O'Hara N, Odili J, Oudit D, Patel A, Patel C, Patel N, Patel P, Peach H, Phillips B, Pinder R, Pinto-Lopes R, Plonczak A, Quinnen N, Rafiq S, Rahman K, Ramjeeawon A, Rinkoff S, Sainsbury D, Schumacher K, Segaren N, Shahzad F, Shariff Z, Siddiqui A, Singh P, Sludden E, Smith JRO, Song M, Stodell M, Tanos G, Taylor K, Taylor L, Thomson D, Tiernan E, Totty JP, Vaingankar N, Toh V, Wensley K, Whitehead C, Whittam A, Wiener M, Wilson A, Wong KY, Wood S, Yeoh T, Yii NW, Yim G, Young R, Zberea D, Jain A. National audit of non-melanoma skin cancer excisions performed by plastic surgery in the UK. Br J Surg 2022; 109:1040-1043. [DOI: 10.1093/bjs/znac232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 05/30/2022] [Indexed: 11/13/2022]
Abstract
A national, multi-centre audit of non-melanoma skin cancer excisions by plastic surgery.
Collapse
Affiliation(s)
- Grant S Nolan
- Department of Plastic and Reconstructive Surgery, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust , Fulwood, Preston , UK
| | - Jonathan A Dunne
- Department of Plastic and Reconstructive Surgery, Charing Cross and St Mary’s Hospitals, Imperial College Healthcare NHS Trust , London , UK
| | - Alice E Lee
- Department of Plastic and Reconstructive Surgery, Charing Cross and St Mary’s Hospitals, Imperial College Healthcare NHS Trust , London , UK
| | - Ryckie G Wade
- Leeds Institute for Medical Research, University of Leeds , Leeds , UK
- Department of Plastic and Reconstructive Surgery, Leeds Teaching Hospitals NHS Trust , Leeds , UK
| | - Ailbhe L Kiely
- Department of Plastic and Reconstructive Surgery, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust , Fulwood, Preston , UK
| | - Rowan O Pritchard Jones
- Department of Plastic and Reconstructive Surgery, Whiston Hospital, St Helens and Knowsley Teaching Hospitals NHS Trust , Prescot , UK
| | - Matthew D Gardiner
- Department of Plastic and Reconstructive Surgery, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Wexham , Slough , UK
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford , UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Abhilash Jain
- Department of Plastic and Reconstructive Surgery, Charing Cross and St Mary’s Hospitals, Imperial College Healthcare NHS Trust , London , UK
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford , UK
| | | |
Collapse
|
19
|
Raghubar AM, Roberts MJ, Wood S, Healy HG, Kassianos AJ, Mallett AJ. Cellular milieu in clear cell renal cell carcinoma. Front Oncol 2022; 12:943583. [PMID: 36313721 PMCID: PMC9614096 DOI: 10.3389/fonc.2022.943583] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Accepted: 09/21/2022] [Indexed: 11/13/2022] Open
Abstract
Clear cell renal cell carcinoma (ccRCC) is globally the most prevalent renal cancer. The cells of origin in ccRCC have been identified as proximal tubular epithelial cells (PTEC); however, the transcriptomic pathways resulting in the transition from normal to malignant PTEC state have remained unclear. Immunotherapy targeting checkpoints have revolutionized the management of ccRCC, but a sustained clinical response is achieved in only a minority of ccRCC patients. This indicates that our understanding of the mechanisms involved in the malignant transition and resistance to immune checkpoint therapy in ccRCC is unclear. This review examines recent single-cell transcriptomics studies of ccRCC to clarify the transition of PTEC in ccRCC development, and the immune cell types, states, and interactions that may limit the response to targeted immune therapy, and finally suggests stromal cells as key drivers in recurrent and locally invasive ccRCC. These and future single-cell transcriptomics studies will continue to clarify the cellular milieu in the ccRCC microenvironment, thus defining actional clinical, therapeutic, and prognostic characteristics of ccRCC.
Collapse
Affiliation(s)
- Arti M. Raghubar
- Kidney Health Service, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia
- Conjoint Internal Medicine Laboratory, Chemical Pathology, Pathology Queensland, Health Support Queensland, Herston, QLD, Australia
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
- Anatomical Pathology, Pathology Queensland, Health Support Queensland, Herston, QLD, Australia
- Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia
| | - Matthew J. Roberts
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
- Department of Urology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia
- Department of Urology, Redcliffe Hospital, Redcliffe, QLD, Australia
- Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia
| | - Simon Wood
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
- Department of Urology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - Helen G. Healy
- Kidney Health Service, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia
- Conjoint Internal Medicine Laboratory, Chemical Pathology, Pathology Queensland, Health Support Queensland, Herston, QLD, Australia
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
| | - Andrew J. Kassianos
- Kidney Health Service, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia
- Conjoint Internal Medicine Laboratory, Chemical Pathology, Pathology Queensland, Health Support Queensland, Herston, QLD, Australia
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
| | - Andrew J. Mallett
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
- Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia
- College of Medicine & Dentistry, James Cook University, Townsville, QLD, Australia
- Department of Renal Medicine, Townsville University Hospital, Townsville, QLD, Australia
- *Correspondence: Andrew J. Mallett,
| |
Collapse
|
20
|
Probst Y, Sulistyoningrum DC, Netting MJ, Gould JF, Wood S, Makrides M, Best KP, Green TJ. Estimated Choline Intakes and Dietary Sources of Choline in Pregnant Australian Women. Nutrients 2022; 14:nu14183819. [PMID: 36145195 PMCID: PMC9503354 DOI: 10.3390/nu14183819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Revised: 09/07/2022] [Accepted: 09/09/2022] [Indexed: 11/29/2022] Open
Abstract
(1) Background: Despite the postulated importance of choline during pregnancy, little is known about the choline intake of Australians during pregnancy. In this study, we estimated dietary intakes of choline in early and late pregnancy, compared those intakes to recommendations, and investigated food sources of choline in a group of pregnant women in Australia. (2) Methods: 103 pregnant women enrolled in a randomized controlled trial. In early pregnancy (12−16 weeks gestation) and late pregnancy (36 weeks gestation), women completed a food frequency questionnaire designed to assess dietary intake over the previous month. (3) Results: Choline intakes and sources were similar in early and late pregnancy. Median choline intake in early pregnancy was 362 mg/day. Of the women, 39% and 25% had choline intakes above the Australian National Health and Medical Research Council (NHMRC) adequate intake (AI) of >440 mg/day and the European Food Safety Authority (EFSA) AI of >480 mg/day for choline in pregnancy, respectively. Eggs, red meat, nuts, legumes, and dairy accounted for 50% of choline intake, with eggs being the most significant contributor at 17%. (4) Conclusions: Few pregnant women in our study met the AI recommended by the NHMRC and EFSA. In Australia, choline intake in pregnancy may need to be improved, but further work to define choline requirements in pregnancy is required.
Collapse
Affiliation(s)
- Yasmine Probst
- School of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong, NSW 2522, Australia
- Illawarra Health and Medical Research Institute, Wollongong, NSW 2522, Australia
| | - Dian C. Sulistyoningrum
- Discipline of Paediatrics, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Merryn J. Netting
- Discipline of Paediatrics, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Jacqueline F. Gould
- Discipline of Paediatrics, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Simon Wood
- Factors Group of Nutritional Products Inc. Research & Development, Burnaby, BC V3K 6Y2, Canada
- School of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA 6102, Australia
| | - Maria Makrides
- Discipline of Paediatrics, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Karen P. Best
- Discipline of Paediatrics, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Tim J. Green
- Discipline of Paediatrics, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA 5000, Australia
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
- Correspondence: ; Tel.: +61-45-244-8438
| |
Collapse
|
21
|
Ramarao-Milne P, Kondrashova O, Patch AM, Nones K, Koufariotis LT, Newell F, Addala V, Lakis V, Holmes O, Leonard C, Wood S, Xu Q, Mukhopadhyay P, Naeini MM, Steinfort D, Williamson JP, Bint M, Pahoff C, Nguyen PT, Twaddell S, Arnold D, Grainge C, Basirzadeh F, Fielding D, Dalley AJ, Chittoory H, Simpson PT, Aoude LG, Bonazzi VF, Patel K, Barbour AP, Fennell DA, Robinson BW, Creaney J, Hollway G, Pearson JV, Waddell N. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. ESMO Open 2022; 7:100540. [PMID: 35849877 PMCID: PMC9463385 DOI: 10.1016/j.esmoop.2022.100540] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 06/07/2022] [Accepted: 06/19/2022] [Indexed: 12/14/2022] Open
Abstract
Background Next-generation sequencing is used in cancer research to identify somatic and germline mutations, which can predict sensitivity or resistance to therapies, and may be a useful tool to reveal drug repurposing opportunities between tumour types. Multigene panels are used in clinical practice for detecting targetable mutations. However, the value of clinical whole-exome sequencing (WES) and whole-genome sequencing (WGS) for cancer care is less defined, specifically as the majority of variants found using these technologies are of uncertain significance. Patients and methods We used the Cancer Genome Interpreter and WGS in 726 tumours spanning 10 cancer types to identify drug repurposing opportunities. We compare the ability of WGS to detect actionable variants, tumour mutation burden (TMB) and microsatellite instability (MSI) by using in silico down-sampled data to mimic WES, a comprehensive sequencing panel and a hotspot mutation panel. Results We reveal drug repurposing opportunities as numerous biomarkers are shared across many solid tumour types. Comprehensive panels identify the majority of approved actionable mutations, with WGS detecting more candidate actionable mutations for biomarkers currently in clinical trials. Moreover, estimated values for TMB and MSI vary when calculated from WGS, WES and panel data, and are dependent on whether all mutations or only non-synonymous mutations were used. Our results suggest that TMB and MSI thresholds should not only be tumour-dependent, but also be sequencing platform-dependent. Conclusions There is a large opportunity to repurpose cancer drugs, and these data suggest that comprehensive sequencing is an invaluable source of information to guide clinical decisions by facilitating precision medicine and may provide a wealth of information for future studies. Furthermore, the sequencing and analysis approach used to estimate TMB may have clinical implications if a hard threshold is used to indicate which patients may respond to immunotherapy. Genome analysis revealed that treatment biomarkers are shared across solid tumours, highlighting repurposing opportunities. Comprehensive panels detect most known biomarkers; however, WGS detects more biomarkers for treatments in clinical trials. TMB is well correlated between sequencing methods, but absolute values vary and are dependent on mutation types considered.
Collapse
Affiliation(s)
- P Ramarao-Milne
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia; Australian e-Health Research Centre, Commonwealth Scientific and Industrial Research Organisation, Brisbane, Australia
| | - O Kondrashova
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - A-M Patch
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - K Nones
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - L T Koufariotis
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - F Newell
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - V Addala
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - V Lakis
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - O Holmes
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - C Leonard
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - S Wood
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Q Xu
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - P Mukhopadhyay
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - M M Naeini
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - D Steinfort
- Department of Thoracic Medicine, Royal Melbourne Hospital, Melbourne, Australia
| | - J P Williamson
- Department of Thoracic Medicine, Liverpool Hospital Sydney, Sydney, Australia
| | - M Bint
- Department of Thoracic Medicine, Sunshine Coast University Hospital, Birtinya, Australia
| | - C Pahoff
- Department of Respiratory Medicine, Gold Coast University Hospital, Southport, Australia
| | - P T Nguyen
- Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia
| | - S Twaddell
- Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
| | - D Arnold
- Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
| | - C Grainge
- Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
| | - F Basirzadeh
- Department of Thoracic Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - D Fielding
- Department of Thoracic Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - A J Dalley
- UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - H Chittoory
- UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - P T Simpson
- UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - L G Aoude
- The University of Queensland Diamantina Institute, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - V F Bonazzi
- The University of Queensland Diamantina Institute, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - K Patel
- The University of Queensland Diamantina Institute, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - A P Barbour
- The University of Queensland Diamantina Institute, Faculty of Medicine, University of Queensland, Brisbane, Australia; Upper Gastro-intestinal Surgical Unit, Department of Surgery, Princess Alexandra Hospital, Brisbane, Australia
| | - D A Fennell
- Cancer Research UK Centre Leicester, University of Leicester & University Hospitals of Leicester NHS Trust, Leicester, UK
| | - B W Robinson
- National Centre for Asbestos Related Disease, Institute of Respiratory Health, University of Western Australia, Nedlands, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia
| | - J Creaney
- National Centre for Asbestos Related Disease, Institute of Respiratory Health, University of Western Australia, Nedlands, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia
| | - G Hollway
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - J V Pearson
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - N Waddell
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
| |
Collapse
|
22
|
Del Vecchio SJ, Urquhart AJ, Dong X, Ellis RJ, Ng KL, Samaratunga H, Gustafson S, Galloway GJ, Gobe GC, Wood S, Mountford CE. Two-dimensional correlated spectroscopy distinguishes clear cell renal cell carcinoma from other kidney neoplasms and non-cancer kidney. Transl Androl Urol 2022; 11:929-942. [PMID: 35958897 PMCID: PMC9360516 DOI: 10.21037/tau-21-1082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Accepted: 05/03/2022] [Indexed: 12/24/2022] Open
Abstract
Background Routinely used clinical scanners, such as computed tomography (CT), magnetic resonance imaging (MRI) and ultrasound (US), are unable to distinguish between aggressive and indolent tumor subtypes in masses localized to the kidney, often leading to surgical overtreatment. The results of the current investigation demonstrate that chemical differences, detected in human kidney biopsies using two-dimensional COrrelated SpectroscopY (2D L-COSY) and evaluated using multivariate statistical analysis, can distinguish these subtypes. Methods One hundred and twenty-six biopsy samples from patients with a confirmed enhancing kidney mass on abdominal imaging were analyzed as part of the training set. A further forty-three samples were used for model validation. In patients undergoing radical nephrectomy, biopsies of non-cancer kidney cortical tissue were also collected as a non-cancer control group. Spectroscopy data were analyzed using multivariate statistical analysis, including principal component analysis (PCA) and orthogonal projection to latent structures with discriminant analysis (OPLS-DA), to identify biomarkers in kidney cancer tissue that was also classified using the gold-standard of histopathology. Results The data analysis methodology showed good separation between clear cell renal cell carcinoma (ccRCC) versus non-clear cell RCC (non-ccRCC) and non-cancer cortical tissue from the kidneys of tumor-bearing patients. Variable Importance for the Projection (VIP) values, and OPLS-DA loadings plots were used to identify chemical species that correlated significantly with the histopathological classification. Model validation resulted in the correct classification of 37/43 biopsy samples, which included the correct classification of 15/17 ccRCC biopsies, achieving an overall predictive accuracy of 86%, Those chemical markers with a VIP value >1.2 were further analyzed using univariate statistical analysis. A subgroup analysis of 47 tumor tissues arising from T1 tumors revealed distinct separation between ccRCC and non-ccRCC tissues. Conclusions This study provides metabolic insights that could have future diagnostic and/or clinical value. The results of this work demonstrate a clear separation between clear cell and non-ccRCC and non-cancer kidney tissue from tumor-bearing patients. The clinical translation of these results will now require the development of a one-dimensional (1D) magnetic resonance spectroscopy (MRS) protocol, for the kidney, using an in vivo clinical MRI scanner.
Collapse
Affiliation(s)
- Sharon J Del Vecchio
- Kidney Disease Research Collaborative, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Australia
| | - Aaron J Urquhart
- Kidney Disease Research Collaborative, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Australia
| | - Xin Dong
- Department of Radiology, Princess Alexandra Hospital, Woolloongabba, Brisbane, Australia
| | - Robert J Ellis
- Kidney Disease Research Collaborative, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Australia
| | | | | | | | - Graham J Galloway
- Herston Imaging Research Facility, The University of Queensland, Brisbane, Australia
| | - Glenda C Gobe
- Kidney Disease Research Collaborative, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Australia.,School of Biomedical Sciences, The University of Queensland, Brisbane, Australia
| | - Simon Wood
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia
| | | |
Collapse
|
23
|
Georges F, Rashad MNH, Stefanko A, Dlamini M, Karki B, Ali SF, Lin PJ, Ko HS, Israel N, Adikaram D, Ahmed Z, Albataineh H, Aljawrneh B, Allada K, Allison S, Alsalmi S, Androic D, Aniol K, Annand J, Atac H, Averett T, Ayerbe Gayoso C, Bai X, Bane J, Barcus S, Bartlett K, Bellini V, Beminiwattha R, Bericic J, Biswas D, Brash E, Bulumulla D, Campbell J, Camsonne A, Carmignotto M, Castellano J, Chen C, Chen JP, Chetry T, Christy ME, Cisbani E, Clary B, Cohen E, Compton N, Cornejo JC, Covrig Dusa S, Crowe B, Danagoulian S, Danley T, De Persio F, Deconinck W, Defurne M, Desnault C, Di D, Duer M, Duran B, Ent R, Fanelli C, Franklin G, Fuchey E, Gal C, Gaskell D, Gautam T, Glamazdin O, Gnanvo K, Gray VM, Gu C, Hague T, Hamad G, Hamilton D, Hamilton K, Hansen O, Hauenstein F, Henry W, Higinbotham DW, Holmstrom T, Horn T, Huang Y, Huber GM, Hyde CE, Ibrahim H, Jen CM, Jin K, Jones M, Kabir A, Keppel C, Khachatryan V, King PM, Li S, Li WB, Liu J, Liu H, Liyanage A, Magee J, Malace S, Mammei J, Markowitz P, McClellan E, Mazouz M, Meddi F, Meekins D, Mesik K, Michaels R, Mkrtchyan A, Montgomery R, Muñoz Camacho C, Myers LS, Nadel-Turonski P, Nazeer SJ, Nelyubin V, Nguyen D, Nuruzzaman N, Nycz M, Obretch OF, Ou L, Palatchi C, Pandey B, Park S, Park K, Peng C, Pomatsalyuk R, Pooser E, Puckett AJR, Punjabi V, Quinn B, Rahman S, Reimer PE, Roche J, Sapkota I, Sarty A, Sawatzky B, Saylor NH, Schmookler B, Shabestari MH, Shahinyan A, Sirca S, Smith GR, Sooriyaarachchilage S, Sparveris N, Spies R, Su T, Subedi A, Sulkosky V, Sun A, Thorne L, Tian Y, Ton N, Tortorici F, Trotta R, Urciuoli GM, Voutier E, Waidyawansa B, Wang Y, Wojtsekhowski B, Wood S, Yan X, Ye L, Ye Z, Yero C, Zhang J, Zhao Y, Zhu P. Deeply Virtual Compton Scattering Cross Section at High Bjorken x_{B}. Phys Rev Lett 2022; 128:252002. [PMID: 35802440 DOI: 10.1103/physrevlett.128.252002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Revised: 03/28/2022] [Accepted: 04/18/2022] [Indexed: 06/15/2023]
Abstract
We report high-precision measurements of the deeply virtual Compton scattering (DVCS) cross section at high values of the Bjorken variable x_{B}. DVCS is sensitive to the generalized parton distributions of the nucleon, which provide a three-dimensional description of its internal constituents. Using the exact analytic expression of the DVCS cross section for all possible polarization states of the initial and final electron and nucleon, and final state photon, we present the first experimental extraction of all four helicity-conserving Compton form factors (CFFs) of the nucleon as a function of x_{B}, while systematically including helicity flip amplitudes. In particular, the high accuracy of the present data demonstrates sensitivity to some very poorly known CFFs.
Collapse
Affiliation(s)
- F Georges
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Stefanko
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - M Dlamini
- Ohio University, Athens, Ohio 45701, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - S F Ali
- Catholic University of America, Washington, DC 20064, USA
| | - P-J Lin
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - H-S Ko
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
- Seoul National University, 1 Gwanak-ro, Gwanak-gu, 08826 Seoul, Korea
| | - N Israel
- Ohio University, Athens, Ohio 45701, USA
| | - D Adikaram
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Z Ahmed
- University of Regina, Regina, Saskatchewan, S4S 0A2 Canada
| | - H Albataineh
- Texas A&M University-Kingsville, Kingsville, Texas 78363, USA
| | - B Aljawrneh
- North Carolina Agricultural and Technical State University, Greensboro, North Carolina 27411, USA
| | - K Allada
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Allison
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
| | - D Androic
- University of Zagreb, Trg Republike Hrvatske 14, 10000 Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | - J Annand
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Ayerbe Gayoso
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - X Bai
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - K Bartlett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Dipartimento di Fisica delle Università degli di Catania, I-95123 Catania, Italy
| | | | - J Bericic
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - E Brash
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J Campbell
- Dalhousie University, Nova Scotia, NS B3H 4R2, Canada
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Carmignotto
- Catholic University of America, Washington, DC 20064, USA
| | - J Castellano
- Florida International University, Miami, Florida 33199, USA
| | - C Chen
- Hampton University, Hampton, Virginia 23669, USA
| | - J-P Chen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - M E Christy
- Hampton University, Hampton, Virginia 23669, USA
| | - E Cisbani
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - B Clary
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - E Cohen
- Tel Aviv University, Tel Aviv-Yafo 6997801, Israel
| | - N Compton
- Ohio University, Athens, Ohio 45701, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Crowe
- North Carolina Central University, Durham, North Carolina 27707, USA
| | - S Danagoulian
- North Carolina Agricultural and Technical State University, Greensboro, North Carolina 27411, USA
| | - T Danley
- Ohio University, Athens, Ohio 45701, USA
| | - F De Persio
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - W Deconinck
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - M Defurne
- CEA Saclay, 91191 Gif-sur-Yvette, France
| | - C Desnault
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - D Di
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Duer
- Tel Aviv University, Tel Aviv-Yafo 6997801, Israel
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Ent
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Fanelli
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - G Franklin
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - O Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - V M Gray
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - G Hamad
- Ohio University, Athens, Ohio 45701, USA
| | - D Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - K Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D W Higinbotham
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Holmstrom
- Longwood University, Farmville, Virginia 23901, USA
| | - T Horn
- Catholic University of America, Washington, DC 20064, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Huang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - G M Huber
- University of Regina, Regina, Saskatchewan, S4S 0A2 Canada
| | - C E Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo 121613, Egypt
| | - C-M Jen
- Virginia Polytechnic Institute & State University, Blacksburg, Virginia 234061, USA
| | - K Jin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Jones
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Kabir
- Kent State University, Kent, Ohio 44240, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Khachatryan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Stony Brook, State University of New York, New York 11794, USA
- Cornell University, Ithaca, New York 14853, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W B Li
- University of Regina, Regina, Saskatchewan, S4S 0A2 Canada
| | - J Liu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - A Liyanage
- Hampton University, Hampton, Virginia 23669, USA
| | - J Magee
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mammei
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | - E McClellan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Mazouz
- Faculté des Sciences de Monastir, Monastir 5019, Tunisia
| | - F Meddi
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Mesik
- Rutgers University, New Brunswick, New Jersey 08854, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Mkrtchyan
- Catholic University of America, Washington, DC 20064, USA
| | - R Montgomery
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - C Muñoz Camacho
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L S Myers
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S J Nazeer
- Hampton University, Hampton, Virginia 23669, USA
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Nuruzzaman
- Hampton University, Hampton, Virginia 23669, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - O F Obretch
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - L Ou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - K Park
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - C Peng
- Duke University, Durham, North Carolina 27708, USA
| | - R Pomatsalyuk
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - E Pooser
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Rahman
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - I Sapkota
- Catholic University of America, Washington, DC 20064, USA
| | - A Sarty
- Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - B Sawatzky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N H Saylor
- Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M H Shabestari
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - A Shahinyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - S Sirca
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - G R Smith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Spies
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
| | - A Subedi
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - V Sulkosky
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Sun
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - L Thorne
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Tian
- Shandong University, Jinan 250100, China
| | - N Ton
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Dipartimento di Fisica delle Università degli di Catania, I-95123 Catania, Italy
| | - R Trotta
- Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, USA
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - E Voutier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - B Waidyawansa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Wang
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Wood
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - X Yan
- Huangshan University, Tunxi, Daizhen Road 245041, China
| | - L Ye
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - Z Ye
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - C Yero
- Florida International University, Miami, Florida 33199, USA
| | - J Zhang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Y Zhao
- Stony Brook, State University of New York, New York 11794, USA
| | - P Zhu
- University of Science and Technology of China, Hefei, Anhui 230026, China
| |
Collapse
|
24
|
Tariq A, McGeorge S, Pearce A, Rhee H, Wood S, Kyle S, Marsh P, Raveenthiran S, Wong D, McBean R, Westera J, Dunglison N, Esler R, Navaratnam A, Yaxley J, Thomas P, Pattison DA, Roberts MJ. Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). Urol Oncol 2022; 40:276.e1-276.e9. [DOI: 10.1016/j.urolonc.2022.03.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 03/06/2022] [Accepted: 03/12/2022] [Indexed: 02/04/2023]
|
25
|
Briot K, Liu J, Williams A, Wood S. OP0048 FIRST INTERIM ANALYSIS OF THE INTERNATIONAL X-LINKED HYPOPHOSPHATAEMIA (XLH) REGISTRY: ADULT POPULATION BASELINE CHARACTERISTICS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundX-Linked Hypophosphataemia (XLH) is a rare, progressive, lifelong, hereditary phosphate wasting disorder characterised by a pathological increase in fibroblast growth factor 23 concentration/activity.1 Despite XLH being increasingly recognised as a chronic progressive disease, there are few data documenting its natural history or the impact of treatment and other medical interventions on patient outcomes.2 The multicentre, international, XLH patient registry was established to address this lack of information in XLH to help inform future clinical practice.ObjectivesTo report data from the first interim analysis of the International XLH Registry (NCT03193476), focusing on baseline characteristics of adults (aged ≥18 years [y]).MethodsThe International XLH Registry was initiated August 2017 to collect information on the natural history of XLH and will run for 10 years, aiming to recruit 1,200 people with XLH. Subjects diagnosed with XLH were enrolled from 81 sites in 16 countries (Last Patient In: 30/11/2020; Database Lock: 29/03/2021). Parameters collected at baseline included demographics, medical/treatment history, and clinical presentation.ResultsIn total, 217 adults were eligible for inclusion in this analysis (18–<30y, n=56; 30–<50y, n=96; ≥50y, n=65); and 150 (69.1%) were female. Mean (SD) age was 41.9y (15.5y); median 41.1y. Mean height was 155.8 cm (n=79); mean weight, 70.0 kg (n=96); mean BMI 26.5 kg/m2 (n=48). Most subjects resided in the UK (50.7%, n=110) and in France (18.9%, n=41). Treatment data were available for 118 subjects: conventional therapy (phosphate salts and active vitamin D), 83.9% (99/118); burosumab, 11.0% (13/118); no treatment recorded 5.1% (6/118). Of 163 subjects with available data, a genetic test result was recorded for 68 (41.7%), of whom 62 (91.2%) had a confirmed PHEX mutation. Data on XLH family history were available for 187 subjects; 56/140 (40.0%) reported their biological mother was affected; and 22/141 (15.6%) reported their biological father was affected. The mean time to diagnosis from first symptoms was longer in older vs younger adults: 18–<30y, 25 months (mo) (n=21); 30–<50y, 21mo (n=21); ≥50y, 112mo (n=13).Retrospective XLH clinical data were available at study entry for 110 adult subjects. Among these subjects, joint conditions were reported by 36.4% (40/110), with osteoarthritis of the knees (60%), hips (42.5%), and shoulders (22.5%) the most frequently affected. Skeletal abnormalities were noted for 71.8% (79/110) of subjects; most common conditions were genu varum 53.2% (42/79), genu valgum 26.6% (21/79), and enthesopathy 21.5% (17/79). Historical fracture data (“yes/no”) were available for 111 subjects; 41 were reported to have had a fracture. Femur fracture was reported for 22 subjects, and hip fractures for 5 subjects.Details of historical orthopaedic surgery were reported for 99 adults; osteotomy was reported for 89 subjects, and hip replacements reported in 14 subjects.ConclusionThe demographics and baseline characteristics of subjects in the International XLH Registry are as expected for adults with XLH. The shorter time to diagnosis in younger vs older adults may indicate improved recognition and diagnosis of XLH in recent years. The analysis of this young population treated with conventional therapy highlights the frequency of musculoskeletal involvement (osteoarthritis, enthesopathies, etc). The information collected within this rare-disease registry during these 10 years provides an exciting opportunity to integrate large-scale real-world evidence into clinical practice, with the aim of improving the care and quality of life of people living with this debilitating disease.References[1]Haffner D, et al. Nat Rev Nephrol 2019;15(7):435–455.[2]Padidela R, et al. Orphanet J Rare Dis. 2020; 15:172.AcknowledgementsThe authors acknowledge the contribution of all members of the International XLH Registry Steering Committee.Disclosure of InterestsKarine Briot Speakers bureau: Speakers bureau from KKI, Amgen, UCB, Alexion, Jonathan Liu Employee of: Employed by Kyowa Kirin International, Angela Williams Employee of: Employed by Kyowa Kirin International, Sue Wood Employee of: Employed by Kyowa Kirin International.
Collapse
|
26
|
Ariceta G, Liu J, Williams A, Wood S, Schnabel D. POS1155 THE INTERNATIONAL X-LINKED HYPOPHOSPHATAEMIA (XLH) REGISTRY: OVERVIEW OF THE DATA SET. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundX-Linked Hypophosphataemia (XLH) is a rare, progressive, lifelong, hereditary renal tubule phosphate-wasting disorder characterised by a pathological increase in fibroblast growth factor 23 concentration/activity.1 Despite XLH being increasingly recognised as a chronic progressive disease, there are few data documenting its natural history or the impact of treatment on patient outcomes.2 The International XLH Registry was established to address this lack of information on XLH to help inform future clinical management. The Registry will collect data to characterise the treatment, burden of disease, disease progression and long-term outcomes of XLH.ObjectivesTo provide an overview and status update of the International XLH Registry as of 31 December 2021.MethodsThe International XLH Registry (NCT03193476) was initiated in August 2017, aims to recruit 1,200 children and adults with XLH, and will run for 10 years. This Registry is an international, multicentre, non-interventional data collection programme and will provide the largest single dataset representing children and adults with XLH. To be eligible for inclusion in the registry, patients must meet all the following criteria:1) Male or female subjects of all ages; 2) Diagnosis of XLH with clinical, radiological, biochemical and/or genetic findings consistent with XLH. The Registry captures any treatment details and clinical outcome variables in patients with XLH and patients are followed for as long as informed consent (and assent, where applicable) and regulatory permissions are maintained. Only data collected during standard routine examinations are recorded within the Registry, and no specific examinations/data entries are mandated.Parameters collected at baseline included demographics, medical and treatment history, and clinical presentation data. The conduct of the International XLH Registry is overseen by 17 Steering Committee physician members representing the region.ResultsAs of 31 December 2021, 1,043 subjects diagnosed with XLH were enrolled from 88 hospital sites in 19 countries. The geographic distribution of subjects is as follows: Belgium n=29, Bulgaria n=7, Czech Republic n=8, Denmark n=23, France n=267, Germany n=79, Hungary n=11, Ireland n=5, Israel n=21, Italy n=88, The Netherlands n=26, Norway n=23, Portugal n=9, Slovakia n=5, Slovenia n=3, Spain n=55, Sweden n=43, Switzerland n=17, and the UK n=324. A further 30 sites are yet to enrol (including sites in Austria and Latvia). Overall, 400 adults (18–29y, n=116; 30–39y, n=81; 40–49y, n=95; 50–59y, n=58; ≥60y, n=50) and 620 paediatric subjects (<5y, n=138; 5–12y, n=321; 13–17y, n=161) have been enrolled (date of birth not reported, n=23). The majority of enrolled subjects are female (648 (62.1%), with 372 male (35.7%) and 23 for whom sex was not reported (2.2%). The quantity of data from the patients included in this Registry will enable ongoing snapshot and prospective analyses to be conducted over the coming years to answer research questions and inform clinical practice.ConclusionThis International XLH Registry forms the largest dataset of subjects with XLH collected to date. Patients have been recruited from a wide geographical region and baseline demographics are consistent with a hereditary X-linked dominant disease. Information collected during the 10-year Registry duration will generate real-world evidence to help inform clinical practice throughout the region, with the aim of improving the care and quality of life of adults and children living with this debilitating disease.References[1]Haffner D, et al. Nat Rev Nephrol 2019;15(7):435–455.[2]Padidela R, et al. Orphanet J Rare Dis. 2020; 15:172.AcknowledgementsAuthors acknowledge the contribution of all International XLH Registry Steering Committee members, and all the investigators participating in the International XLH Registry.Disclosure of InterestsGema Ariceta Speakers bureau: I have received honoraria for lectures, presentations, or educational events from Alexion Pharmaceuticals, Recordati Rare Disease, Advicenne, Chiesi, Kyowa Kirin, Consultant of: I have participated on Advisory Boards for Alexion Pharmaceuticals, Advicenne, Chiesi, Dicerna, and Alnylam., Jonathan Liu Employee of: Employee of Kyowa Kirin International, Angela Williams Employee of: Employee of Kyowa Kirin International, Sue Wood Employee of: Employee of Kyowa Kirin International, Dirk Schnabel Speakers bureau: I received an honorarium from various companies for scientific lectures (i.e. Ascendis, BioMarin, Ferring Pharma, Hexal / Sandoz, Ipsen Pharma, Kyowa Kirin, Merck Serono, Novo Nordisk), Consultant of: BioMarin, Kyowa Kirin
Collapse
|
27
|
Corbett M, Wood S. OP-9 Subconjunctival silicone oil - presentation, histology and surgical management. BMJ Open Ophthalmol 2022; 7:A3. [PMID: 36161810 DOI: 10.1136/bmjophth-2022-bcm.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023] Open
Abstract
UNLABELLED *Correspondence - Melanie Corbett: melanie@corbwood.co.uk OBJECTIVE: To describe the clinical and histological findings in subconjunctival silicone oil leakage, and a surgical technique for its management. METHOD A 60-year-old woman with a chronic macula-off detachment underwent two pars plana vitrectomies four months apart. The silicone oil inserted during the first was replaced by heavy silicone (Oxane HD) at the second, with unsutured sclerostomy ports. One month later silicone oil cysts were noted under the conjunctiva. RESULTS Symptoms were grittiness, dryness and heaviness with occasional severe pain. Multiple oil globules 0.2 - 2mm in diameter were tightly packed beneath the conjunctiva in two quadrants, extending from limbus to peripheral bulbar conjunctiva.Tenons tissue containing silicone globules was isolated by dissecting planes superficially, immediately beneath the conjunctival basement membrane, and deep, immediately above the sclera. The tissue sheet was mobilised and excised posteriorly at the junction with healthy tissue.Histology revealed sheets of connective tissue with densely packed tiny lacunae, and intermittent large lacunae with fibrous walls. Inflammatory cells were scattered in between. DISCUSSION Injectable medical grade silicone oil is only approved for intravitreal use. When injected into breasts, buttocks or face, or following implant rupture, it can migrate causing inflammation, contracture, calcification, embolism and death. It is difficult to remove surgically as it is viscous and adherent, requiring surfactants. CONCLUSION Leakage of silicone oil from a sclerostomy is a rare complication of intravitreal use. It densely infiltrates subconjunctival tissues, causing irritation and heaviness. With careful dissection, the tissues can be removed en bloc with resolution of symptoms.
Collapse
Affiliation(s)
| | - Simon Wood
- Department of Plastic and Reconstructive Surgery, Imperial NHS Trust, London, UK
| |
Collapse
|
28
|
Hakim D, Boland M, Grant Y, Kovacevic L, Mossalios E, Henry F, Wood S, Thiruchelvam P, Leff D. Financial impact of post-mastectomy radiotherapy after immediate autologous breast reconstruction. Eur J Surg Oncol 2022. [DOI: 10.1016/j.ejso.2022.03.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
29
|
Abrams D, Albataineh H, Aljawrneh BS, Alsalmi S, Androic D, Aniol K, Armstrong W, Arrington J, Atac H, Averett T, Gayoso CA, Bai X, Bane J, Barcus S, Beck A, Bellini V, Bhatt H, Bhetuwal D, Biswas D, Blyth D, Boeglin W, Bulumulla D, Butler J, Camsonne A, Carmignotto M, Castellanos J, Chen JP, Cohen EO, Covrig S, Craycraft K, Cruz-Torres R, Dongwi B, Duran B, Dutta D, Fuchey E, Gal C, Gautam TN, Gilad S, Gnanvo K, Gogami T, Gomez J, Gu C, Habarakada A, Hague T, Hansen JO, Hattawy M, Hauenstein F, Higinbotham DW, Holt RJ, Hughes EW, Hyde C, Ibrahim H, Jian S, Joosten S, Karki A, Karki B, Katramatou AT, Keith C, Keppel C, Khachatryan M, Khachatryan V, Khanal A, Kievsky A, King D, King PM, Korover I, Kulagin SA, Kumar KS, Kutz T, Lashley-Colthirst N, Li S, Li W, Liu H, Liuti S, Liyanage N, Markowitz P, McClellan RE, Meekins D, Beck SMT, Meziani ZE, Michaels R, Mihovilovic M, Nelyubin V, Nguyen D, Nycz M, Obrecht R, Olson M, Owen VF, Pace E, Pandey B, Pandey V, Paolone M, Papadopoulou A, Park S, Paul S, Petratos GG, Petti R, Piasetzky E, Pomatsalyuk R, Premathilake S, Puckett AJR, Punjabi V, Ransome RD, Rashad MNH, Reimer PE, Riordan S, Roche J, Salmè G, Santiesteban N, Sawatzky B, Scopetta S, Schmidt A, Schmookler B, Segal J, Segarra EP, Shahinyan A, Širca S, Sparveris N, Su T, Suleiman R, Szumila-Vance H, Tadepalli AS, Tang L, Tireman W, Tortorici F, Urciuoli GM, Wojtsekhowski B, Wood S, Ye ZH, Ye ZY, Zhang J. Measurement of the Nucleon F_{2}^{n}/F_{2}^{p} Structure Function Ratio by the Jefferson Lab MARATHON Tritium/Helium-3 Deep Inelastic Scattering Experiment. Phys Rev Lett 2022; 128:132003. [PMID: 35426713 DOI: 10.1103/physrevlett.128.132003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Revised: 01/23/2022] [Accepted: 02/09/2022] [Indexed: 06/14/2023]
Abstract
The ratio of the nucleon F_{2} structure functions, F_{2}^{n}/F_{2}^{p}, is determined by the MARATHON experiment from measurements of deep inelastic scattering of electrons from ^{3}H and ^{3}He nuclei. The experiment was performed in the Hall A Facility of Jefferson Lab using two high-resolution spectrometers for electron detection, and a cryogenic target system which included a low-activity tritium cell. The data analysis used a novel technique exploiting the mirror symmetry of the two nuclei, which essentially eliminates many theoretical uncertainties in the extraction of the ratio. The results, which cover the Bjorken scaling variable range 0.19<x<0.83, represent a significant improvement compared to previous SLAC and Jefferson Lab measurements for the ratio. They are compared to recent theoretical calculations and empirical determinations of the F_{2}^{n}/F_{2}^{p} ratio.
Collapse
Affiliation(s)
- D Abrams
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Albataineh
- Texas A & M University, Kingsville, Texas 78363, USA
| | - B S Aljawrneh
- North Carolina A & T State University, Greensboro, North Carolina 27411, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
- King Saud University, Riyadh 11451, Kingdom of Saudi Arabia
| | - D Androic
- University of Zagreb, 10000 Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, California 90032, USA
| | - W Armstrong
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Arrington
- Argonne National Laboratory, Lemont, Illinois 60439, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- William & Mary, Williamsburg, Virginia 23187, USA
| | | | - X Bai
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- William & Mary, Williamsburg, Virginia 23187, USA
| | - A Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | - H Bhatt
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - D Bhetuwal
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - D Blyth
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - W Boeglin
- Florida International University, Miami, Florida 33199, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J Butler
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - A Camsonne
- Jefferson Lab, Newport News, Virginia 23606, USA
| | | | - J Castellanos
- Florida International University, Miami, Florida 33199, USA
| | - J-P Chen
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - E O Cohen
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv, Israel
| | - S Covrig
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - K Craycraft
- William & Mary, Williamsburg, Virginia 23187, USA
| | - R Cruz-Torres
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B Dongwi
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D Dutta
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T N Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - S Gilad
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T Gogami
- Tohoku University, Sendai 980-8576, Japan
| | - J Gomez
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Habarakada
- Hampton University, Hampton, Virginia 23669, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - J-O Hansen
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Hattawy
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | | | - R J Holt
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - E W Hughes
- Columbia University, New York, New York 10027, USA
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo, Giza 12613 Egypt
| | - S Jian
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Joosten
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A Karki
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | | | - C Keith
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - C Keppel
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V Khachatryan
- Stony Brook, State University of New York, New York 11794, USA
| | - A Khanal
- Florida International University, Miami, Florida 33199, USA
| | - A Kievsky
- Istituto Nazionale di Fisica Nucleare, Sezione di Pisa, 56127 Pisa, Italy
| | - D King
- Syracuse University, Syracuse, New York 13244, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - I Korover
- Nuclear Research Center-Negev, Beer-Sheva 84190, Israel
| | - S A Kulagin
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - K S Kumar
- Stony Brook, State University of New York, New York 11794, USA
| | - T Kutz
- Stony Brook, State University of New York, New York 11794, USA
| | | | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W Li
- University of Regina, Regina, Saskatchewan S4S 0A2, Canada
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - S Liuti
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Liyanage
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | | | - D Meekins
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - S Mey-Tal Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Z-E Meziani
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Michaels
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Mihovilovic
- Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana 1000, Slovenia
- Jožef Stefan Institute, Ljubljana, Slovenia
- Institut für Kernphysik, Johannes Gutenberg-Universität, Mainz 55122, Germany
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - R Obrecht
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Olson
- Saint Norbert College, De Pere, Wisconsin 54115, USA
| | - V F Owen
- William & Mary, Williamsburg, Virginia 23187, USA
| | - E Pace
- University of Rome Tor Vergata and INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - V Pandey
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - M Paolone
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A Papadopoulou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - S Paul
- William & Mary, Williamsburg, Virginia 23187, USA
| | | | - R Petti
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - E Piasetzky
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv, Israel
| | - R Pomatsalyuk
- Institute of Physics and Technology, 61108 Kharkov, Ukraine
| | - S Premathilake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - R D Ransome
- Rutgers, The State University of New Jersey, Piscataway, New Jersey 08855, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - P E Reimer
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - S Riordan
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - G Salmè
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma, 00185 Rome, Italy
| | - N Santiesteban
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - B Sawatzky
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - S Scopetta
- University of Perugia and INFN, Sezione di Perugia, 06123 Perugia, Italy
| | - A Schmidt
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J Segal
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - E P Segarra
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Shahinyan
- Yerevan Physics Institute, Yerevan 375036, Armenia
| | - S Širca
- Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana 1000, Slovenia
- Jožef Stefan Institute, Ljubljana, Slovenia
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
- Shandong Institute of Advanced Technology, Jinan, Shandong 250100, China
| | - R Suleiman
- Jefferson Lab, Newport News, Virginia 23606, USA
| | | | - A S Tadepalli
- Rutgers, The State University of New Jersey, Piscataway, New Jersey 08855, USA
| | - L Tang
- Hampton University, Hampton, Virginia 23669, USA
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - W Tireman
- Northern Michigan University, Marquette, Michigan 49855, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma, 00185 Rome, Italy
| | | | - S Wood
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - Z H Ye
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - Z Y Ye
- University of Illinois-Chicago, Chicago, Illinois 60607, USA
| | - J Zhang
- Stony Brook, State University of New York, New York 11794, USA
| |
Collapse
|
30
|
Willis TA, Wood S, Brehaut J, Colquhoun H, Brown B, Lorencatto F, Foy R. Opportunities to improve the impact of two national clinical audit programmes: a theory-guided analysis. Implement Sci Commun 2022; 3:32. [PMID: 35313992 PMCID: PMC8935621 DOI: 10.1186/s43058-022-00275-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 02/19/2022] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Audit and feedback is widely used in healthcare improvement, with evidence of modest yet potentially important effects upon professional practice. There are approximately 60 national clinical audit programmes in the UK. These programmes often develop and adapt new ways of delivering feedback to optimise impacts on clinical practice. Two such programmes, the National Diabetes Audit (NDA) and the Trauma Audit Research Network (TARN), recently introduced changes to their delivery of feedback. We assessed the extent to which the design of these audit programmes and their recent changes were consistent with best practice according to the Clinical Performance Feedback Intervention Theory (CP-FIT). This comprehensive framework specifies how variables related to the feedback itself, the recipient, and the context operate via explanatory mechanisms to influence feedback success.
Methods
We interviewed 19 individuals with interests in audit and feedback, including researchers, audit managers, healthcare staff, and patient and public representatives. This range of expert perspectives enabled a detailed exploration of feedback from the audit programmes. We structured interviews around the CP-FIT feedback cycle and its component processes (e.g. Data collection and analysis, Interaction). Our rapid analytic approach explored the extent to which both audits applied features consistent with CP-FIT.
Results
Changes introduced by the audit programmes were consistent with CP-FIT. Specifically, the NDA’s increased frequency of feedback augmented existing strengths, such as automated processes (CP-FIT component: Data collection and analysis) and being a credible source of feedback (Acceptance). TARN’s new analytic tool allowed greater interactivity, enabling recipients to interrogate their data (Verification; Acceptance). We also identified scope for improvement in feedback cycles, such as targeting of feedback recipients (Interaction) and feedback complexity (Perception) for the NDA and specifying recommendations (Intention) and demonstrating impact (Clinical performance improvement) for TARN.
Conclusions
The changes made by the two audit programmes appear consistent with suggested best practice, making clinical improvement more likely. However, observed weaknesses in the feedback cycle may limit the benefits of these changes. Applying CP-FIT via a rapid analysis approach helps identify strengths and remediable weaknesses in the design of audit programmes that can be shared with them in a timely manner.
Collapse
|
31
|
Christy ME, Gautam T, Ou L, Schmookler B, Wang Y, Adikaram D, Ahmed Z, Albataineh H, Ali SF, Aljawrneh B, Allada K, Allison SL, Alsalmi S, Androic D, Aniol K, Annand J, Arrington J, Atac H, Averett T, Ayerbe Gayoso C, Bai X, Bane J, Barcus S, Bartlett K, Bellini V, Beminiwattha R, Bericic J, Bhatt H, Bhetuwal D, Biswas D, Brash E, Bulumulla D, Camacho CM, Campbell J, Camsonne A, Carmignotto M, Castellanos J, Chen C, Chen JP, Chetry T, Cisbani E, Clary B, Cohen E, Compton N, Cornejo JC, Covrig Dusa S, Crowe B, Danagoulian S, Danley T, Deconinck W, Defurne M, Desnault C, Di D, Dlamini M, Duer M, Duran B, Ent R, Fanelli C, Fuchey E, Gal C, Gaskell D, Georges F, Gilad S, Glamazdin O, Gnanvo K, Gramolin AV, Gray VM, Gu C, Habarakada A, Hague T, Hamad G, Hamilton D, Hamilton K, Hansen O, Hauenstein F, Hernandez AV, Henry W, Higinbotham DW, Holmstrom T, Horn T, Huang Y, Huber GM, Hyde C, Ibrahim H, Israel N, Jen CM, Jin K, Jones M, Kabir A, Karki B, Keppel C, Khachatryan V, King PM, Li S, Li W, Liu H, Liu J, Liyanage AH, Mack D, Magee J, Malace S, Mammei J, Markowitz P, Mayilyan S, McClellan E, Meddi F, Meekins D, Mesick K, Michaels R, Mkrtchyan A, Moffit B, Montgomery R, Myers LS, Nadel-Turonski P, Nazeer SJ, Nelyubin V, Nguyen D, Nuruzzaman N, Nycz M, Obrecht RF, Ohanyan K, Palatchi C, Pandey B, Park K, Park S, Peng C, Persio FD, Pomatsalyuk R, Pooser E, Puckett AJR, Punjabi V, Quinn B, Rahman S, Rashad MNH, Reimer PE, Riordan S, Roche J, Sapkota I, Sarty A, Sawatzky B, Saylor NH, Shabestari MH, Shahinyan A, Širca S, Smith GR, Sooriyaarachchilage S, Sparveris N, Spies R, Stefanko A, Su T, Subedi A, Sulkosky V, Sun A, Tan Y, Thorne L, Ton N, Tortorici F, Trotta R, Uniyal R, Urciuoli GM, Voutier E, Waidyawansa B, Wojtsekhowski B, Wood S, Yan X, Ye L, Ye ZH, Yero C, Zhang J, Zhao YX, Zhu P. Form Factors and Two-Photon Exchange in High-Energy Elastic Electron-Proton Scattering. Phys Rev Lett 2022; 128:102002. [PMID: 35333083 DOI: 10.1103/physrevlett.128.102002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 11/06/2021] [Accepted: 01/31/2022] [Indexed: 06/14/2023]
Abstract
We present new precision measurements of the elastic electron-proton scattering cross section for momentum transfer (Q^{2}) up to 15.75 (GeV/c)^{2}. Combined with existing data, these provide an improved extraction of the proton magnetic form factor at high Q^{2} and double the range over which a longitudinal or transverse separation of the cross section can be performed. The difference between our results and polarization data agrees with that observed at lower Q^{2} and attributed to hard two-photon exchange (TPE) effects, extending to 8 (GeV/c)^{2} the range of Q^{2} for which a discrepancy is established at >95% confidence. We use the discrepancy to quantify the size of TPE contributions needed to explain the cross section at high Q^{2}.
Collapse
Affiliation(s)
- M E Christy
- Hampton University, Hampton, Virginia 23669, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - L Ou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Y Wang
- William and Mary, Williamsburg, Virginia 23185, USA
| | - D Adikaram
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Z Ahmed
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - H Albataineh
- Texas A & M University, Kingsville, Texas 77843, USA
| | - S F Ali
- Catholic University of America, Washington, District of Columbia 20064, USA
| | - B Aljawrneh
- North Carolina A&T State University, Greensboro, North Carolina 27411, USA
- Al Zaytoonah University of Jordan, Amman 11733, Jordan
| | - K Allada
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S L Allison
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
| | - D Androic
- University of Zagreb, Trg Republike Hrvatske 14, 10000, Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | - J Annand
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - J Arrington
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- William and Mary, Williamsburg, Virginia 23185, USA
| | | | - X Bai
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- William and Mary, Williamsburg, Virginia 23185, USA
| | - K Bartlett
- William and Mary, Williamsburg, Virginia 23185, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Department of Physics and Astronomy, I-95123 Catania, Italy
| | | | - J Bericic
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Bhatt
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - D Bhetuwal
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - E Brash
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - C M Camacho
- Institut de Physique Nucleaire, 15 Rue Georges Clemenceau, 91400 Orsay, France
| | - J Campbell
- Dalhousie University, Nova Scotia NS B3H 4R2, Canada
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Carmignotto
- Catholic University of America, Washington, DC 20064, USA
| | - J Castellanos
- Florida International University, Miami, Florida 33199, USA
| | - C Chen
- Hampton University, Hampton, Virginia 23669, USA
| | - J-P Chen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - E Cisbani
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - B Clary
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - E Cohen
- Tel Aviv University, Tel Aviv-Yafo 69978, Israel
| | - N Compton
- Ohio University, Athens, Ohio 45701, USA
| | - J C Cornejo
- William and Mary, Williamsburg, Virginia 23185, USA
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Crowe
- North Carolina Central University, Durham, North Carolina 27707, USA
| | - S Danagoulian
- North Carolina A&T State University, Greensboro, North Carolina 27411, USA
| | - T Danley
- Ohio University, Athens, Ohio 45701, USA
| | - W Deconinck
- William and Mary, Williamsburg, Virginia 23185, USA
| | - M Defurne
- CEA Saclay, 91191 Gif-sur-Yvette, France
| | - C Desnault
- Institut de Physique Nucleaire, 15 Rue Georges Clemenceau, 91400 Orsay, France
| | - D Di
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - M Dlamini
- Ohio University, Athens, Ohio 45701, USA
| | - M Duer
- Tel Aviv University, Tel Aviv-Yafo 69978, Israel
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Ent
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Fanelli
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Georges
- Ecole Centrale Paris, 3 Rue Joliot Curie, 91190 Gif-sur-Yvette, France
| | - S Gilad
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - O Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - A V Gramolin
- Boston University, Boston, Massachusetts 02215, USA
| | - V M Gray
- William and Mary, Williamsburg, Virginia 23185, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - A Habarakada
- Hampton University, Hampton, Virginia 23669, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - G Hamad
- Ohio University, Athens, Ohio 45701, USA
| | - D Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - K Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A V Hernandez
- Catholic University of America, Washington, DC 20064, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D W Higinbotham
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Holmstrom
- Randolph Macon College, Ashland, Virginia 23005, USA
| | - T Horn
- Catholic University of America, Washington, DC 20064, USA
| | - Y Huang
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - G M Huber
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo, 12613, Egypt
| | - N Israel
- Ohio University, Athens, Ohio 45701, USA
| | - C-M Jen
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 234061, USA
| | - K Jin
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - M Jones
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Kabir
- Kent State University, Kent, Ohio 44240, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Khachatryan
- Stony Brook, State University of New York, New York 11794, USA
- Cornell University, Ithaca, New York 14853, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W Li
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - J Liu
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - A H Liyanage
- Hampton University, Hampton, Virginia 23669, USA
| | - D Mack
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Magee
- William and Mary, Williamsburg, Virginia 23185, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mammei
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | - S Mayilyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - E McClellan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Meddi
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Mesick
- Rutgers University, New Brunswick, New Jersey 08854, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Mkrtchyan
- Catholic University of America, Washington, DC 20064, USA
| | - B Moffit
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - R Montgomery
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - L S Myers
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S J Nazeer
- Hampton University, Hampton, Virginia 23669, USA
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - N Nuruzzaman
- Hampton University, Hampton, Virginia 23669, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - R F Obrecht
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - K Ohanyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - K Park
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - C Peng
- Duke University, Durham, North Carolina 27708, USA
| | - F D Persio
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - R Pomatsalyuk
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - E Pooser
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Rahman
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - P E Reimer
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - S Riordan
- Stony Brook, State University of New York, New York 11794, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - I Sapkota
- Catholic University of America, Washington, DC 20064, USA
| | - A Sarty
- Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - B Sawatzky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N H Saylor
- Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - M H Shabestari
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - A Shahinyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - S Širca
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - G R Smith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Spies
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - A Stefanko
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
| | - A Subedi
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - V Sulkosky
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Sun
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Tan
- Shandong University, Shandong, Jinan 250100, China
| | - L Thorne
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - N Ton
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Department of Physics and Astronomy, I-95123 Catania, Italy
| | - R Trotta
- Duquesne University, Pittsburgh, Pennsylvania 15282, USA
| | - R Uniyal
- Catholic University of America, Washington, DC 20064, USA
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - E Voutier
- Institut de Physique Nucleaire, 15 Rue Georges Clemenceau, 91400 Orsay, France
| | - B Waidyawansa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Wood
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - X Yan
- Huangshan University, 44 Daizhen Road, Tunxi District, Huangshan, Anhui Province, China
| | - L Ye
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - Z H Ye
- University of Virginia, Charlottesville, Virginia 232904, USA
- Tsinghua University, 30 Shuangqing Rd, Haidian District, Beijing 100190, China
| | - C Yero
- Florida International University, Miami, Florida 33199, USA
| | - J Zhang
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - Y X Zhao
- Stony Brook, State University of New York, New York 11794, USA
| | - P Zhu
- University of Science and Technology of China, Hefei, Anhui 230026, China
| |
Collapse
|
32
|
Wood S, Newman M, Batting M, Barker K. Is the squat test a valid and reliable test for the diagnosis of femoral acetabular impingement? A systematic review. Physiotherapy 2022. [DOI: 10.1016/j.physio.2021.12.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Dlamini M, Karki B, Ali SF, Lin PJ, Georges F, Ko HS, Israel N, Rashad MNH, Stefanko A, Adikaram D, Ahmed Z, Albataineh H, Aljawrneh B, Allada K, Allison S, Alsalmi S, Androic D, Aniol K, Annand J, Atac H, Averett T, Ayerbe Gayoso C, Bai X, Bane J, Barcus S, Bartlett K, Bellini V, Beminiwattha R, Bericic J, Biswas D, Brash E, Bulumulla D, Campbell J, Camsonne A, Carmignotto M, Castellano J, Chen C, Chen JP, Chetry T, Christy ME, Cisbani E, Clary B, Cohen E, Compton N, Cornejo JC, Covrig Dusa S, Crowe B, Danagoulian S, Danley T, De Persio F, Deconinck W, Defurne M, Desnault C, Di D, Duer M, Duran B, Ent R, Fanelli C, Franklin G, Fuchey E, Gal C, Gaskell D, Gautam T, Glamazdin O, Gnanvo K, Gray VM, Gu C, Hague T, Hamad G, Hamilton D, Hamilton K, Hansen O, Hauenstein F, Henry W, Higinbotham DW, Holmstrom T, Horn T, Huang Y, Huber GM, Hyde C, Ibrahim H, Jen CM, Jin K, Jones M, Kabir A, Keppel C, Khachatryan V, King PM, Li S, Li W, Liu J, Liu H, Liyanage A, Magee J, Malace S, Mammei J, Markowitz P, McClellan E, Meddi F, Meekins D, Mesik K, Michaels R, Mkrtchyan A, Montgomery R, Muñoz Camacho C, Myers LS, Nadel-Turonski P, Nazeer SJ, Nelyubin V, Nguyen D, Nuruzzaman N, Nycz M, Obretch OF, Ou L, Palatchi C, Pandey B, Park S, Park K, Peng C, Pomatsalyuk R, Pooser E, Puckett AJR, Punjabi V, Quinn B, Rahman S, Reimer PE, Roche J, Sapkota I, Sarty A, Sawatzky B, Saylor NH, Schmookler B, Shabestari MH, Shahinyan A, Sirca S, Smith GR, Sooriyaarachchilage S, Sparveris N, Spies R, Su T, Subedi A, Sulkosky V, Sun A, Thorne L, Tian Y, Ton N, Tortorici F, Trotta R, Urciuoli GM, Voutier E, Waidyawansa B, Wang Y, Wojtsekhowski B, Wood S, Yan X, Ye L, Ye Z, Yero C, Zhang J, Zhao Y, Zhu P. Deep Exclusive Electroproduction of π^{0} at High Q^{2} in the Quark Valence Regime. Phys Rev Lett 2021; 127:152301. [PMID: 34678020 DOI: 10.1103/physrevlett.127.152301] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 06/07/2021] [Accepted: 08/17/2021] [Indexed: 06/13/2023]
Abstract
We report measurements of the exclusive neutral pion electroproduction cross section off protons at large values of x_{B} (0.36, 0.48, and 0.60) and Q^{2} (3.1 to 8.4 GeV^{2}) obtained from Jefferson Lab Hall A experiment E12-06-014. The corresponding structure functions dσ_{T}/dt+εdσ_{L}/dt, dσ_{TT}/dt, dσ_{LT}/dt, and dσ_{LT^{'}}/dt are extracted as a function of the proton momentum transfer t-t_{min}. The results suggest the amplitude for transversely polarized virtual photons continues to dominate the cross section throughout this kinematic range. The data are well described by calculations based on transversity generalized parton distributions coupled to a helicity flip distribution amplitude of the pion, thus providing a unique way to probe the structure of the nucleon.
Collapse
Affiliation(s)
- M Dlamini
- Ohio University, Athens, Ohio 45701, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - S F Ali
- Catholic University of America, Washington, DC 20064, USA
| | - P-J Lin
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - F Georges
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - H-S Ko
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
- Seoul National University, 1 Gwanak-ro, Gwanak-gu, 08826 Seoul, Korea
| | - N Israel
- Ohio University, Athens, Ohio 45701, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Stefanko
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - D Adikaram
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Z Ahmed
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - H Albataineh
- Texas A&M University-Kingsville, Kingsville, Texas 78363, USA
| | - B Aljawrneh
- North Carolina Ag. and Tech. State University, Greensboro, North Carolina 27411, USA
| | - K Allada
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Allison
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
| | - D Androic
- University of Zagreb, Trg Republike Hrvatske 14, 10000 Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | - J Annand
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Ayerbe Gayoso
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - X Bai
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - K Bartlett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Dipt. Di Fisica delle Uni. di Catania, I-95123 Catania, Italy
| | | | - J Bericic
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - E Brash
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J Campbell
- Dalhousie University, Nova Scotia B3H 4R2, Canada
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Carmignotto
- Catholic University of America, Washington, DC 20064, USA
| | - J Castellano
- Florida International University, Miami, Florida 33199, USA
| | - C Chen
- Hampton University, Hampton, Virginia 23669, USA
| | - J-P Chen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - M E Christy
- Hampton University, Hampton, Virginia 23669, USA
| | - E Cisbani
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - B Clary
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - E Cohen
- Tel Aviv University, Tel Aviv 699780 1, Israel
| | - N Compton
- Ohio University, Athens, Ohio 45701, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Crowe
- North Carolina Central University, Durham, North Carolina 27707, USA
| | - S Danagoulian
- North Carolina Ag. and Tech. State University, Greensboro, North Carolina 27411, USA
| | - T Danley
- Ohio University, Athens, Ohio 45701, USA
| | - F De Persio
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - W Deconinck
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - M Defurne
- CEA Saclay, 91191 Gif-sur-Yvette, France
| | - C Desnault
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - D Di
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Duer
- Tel Aviv University, Tel Aviv 699780 1, Israel
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Ent
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Fanelli
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - G Franklin
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - O Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - V M Gray
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - G Hamad
- Ohio University, Athens, Ohio 45701, USA
| | - D Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - K Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D W Higinbotham
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Holmstrom
- Randolph Macon College, Ashlan, Virginia 23005, USA
| | - T Horn
- Catholic University of America, Washington, DC 20064, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Huang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - G M Huber
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo 121613, Egypt
| | - C-M Jen
- Virginia Polytechnic Institute & State University, Blacksburg, Virginia 234061, USA
| | - K Jin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Jones
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Kabir
- Kent State University, Kent, Ohio 44240, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Khachatryan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Stony Brook, State University of New York, New York 11794, USA
- Cornell University, Ithaca, New York 14853, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W Li
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - J Liu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - A Liyanage
- Hampton University, Hampton, Virginia 23669, USA
| | - J Magee
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mammei
- University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | - E McClellan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Meddi
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Mesik
- Rutgers University, New Brunswick, New Jersey 08854, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Mkrtchyan
- Catholic University of America, Washington, DC 20064, USA
| | - R Montgomery
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - C Muñoz Camacho
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L S Myers
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S J Nazeer
- Hampton University, Hampton, Virginia 23669, USA
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Nuruzzaman
- Hampton University, Hampton, Virginia 23669, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - O F Obretch
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - L Ou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - K Park
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - C Peng
- Duke University, Durham, North Carolina 27708, USA
| | - R Pomatsalyuk
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - E Pooser
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Rahman
- University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - I Sapkota
- Catholic University of America, Washington, DC 20064, USA
| | - A Sarty
- Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - B Sawatzky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N H Saylor
- Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M H Shabestari
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - A Shahinyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - S Sirca
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - G R Smith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Spies
- University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
| | - A Subedi
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - V Sulkosky
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Sun
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - L Thorne
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Tian
- Shandong University, Jinan, Shandong, 250100, China
| | - N Ton
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Dipt. Di Fisica delle Uni. di Catania, I-95123 Catania, Italy
| | - R Trotta
- Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, USA
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - E Voutier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - B Waidyawansa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Wang
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Wood
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - X Yan
- Huangshan University, Huangshan, Anhui, 245041, China
| | - L Ye
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - Z Ye
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - C Yero
- Florida International University, Miami, Florida 33199, USA
| | - J Zhang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Y Zhao
- Stony Brook, State University of New York, New York 11794, USA
| | - P Zhu
- University of Science and Technology of China, Hefei, Anhui 230026, China
| |
Collapse
|
34
|
Al-Shinnag M, Marfan H, Susman R, Wakeling J, Gustafson S, Wood S, Mallett AJ. Birt-Hogg-Dubé Syndrome and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome: An Effective Multidisciplinary Approach to Hereditary Renal Cancer Predisposing Syndromes. Front Oncol 2021; 11:738822. [PMID: 34604083 PMCID: PMC8481944 DOI: 10.3389/fonc.2021.738822] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Accepted: 08/20/2021] [Indexed: 01/21/2023] Open
Abstract
Aim We aimed to describe and analyse clinical features, characteristics, and adherence to surveillance guidelines in an Australian Birt-Hogg-Dubé syndrome (BHD) and hereditary leiomyomatosis and renal cell cancer (HLRCC) cohort. Methods All identified patients with a diagnosis of BHD or HLRCC at RBWH 01/01/2014-01/09/2019 were included (HREC/17/QRBW/276). All patients were initially assessed and counselled by a clinical geneticist and then referred to an adult nephrologist. Baseline and incidental clinical variables were extracted and analysed. Results Fifty-seven patients were identified (28 BHD, 29 HLRCC) with a median age of 47 years. The median and cumulative follow-up were 1 and 99 years, respectively. Baseline renal MRI occurred in 40/57 patients, and 33/57 had regular MRI as per the national guidelines (eviQ). Of 18/57 without baseline imaging, nine were yet to have imaging, seven were lost follow-up, and two patients had logistic difficulties. RCC was diagnosed in 11/57 patients: two of 28 with BHD were diagnosed with RCC aged 73 and 77, both prior to commencement of surveillance. Nine of 29 patients with HLRCC were diagnosed with RCC (one of 29 during surveillance at 47 years of age) and eight of 29 prior to commencement of surveillance (11-55 years). Amongst BHD patients, cutaneous fibrofolliculomas were noted in 15 patients, lung cysts were detected in seven patients, spontaneous pneumothoraces in five patients, and parotid oncocytoma in two of 28. Amongst those with HLRCC, cutaneous leiomyomas were noted in 19/29, cutaneous leiomyosarcoma diagnosed in one of 29, and uterine fibroids in 13 female patients. Conclusion Evidence-based RCC screening in BHD and HLRCC cohort is feasible and able to identify incidental renal lesions. Multidisciplinary patient management enables expedited genetic counselling, diagnosis, longitudinal screening, and RCC management. The success of this clinical model warrants consideration of undertaking longitudinal screening of BHD and HLRCC patients by nephrologists.
Collapse
Affiliation(s)
- Mohammad Al-Shinnag
- Faculty of Medicine, The University of Queensland, Herston, QLD, Australia.,Genetic Health Queensland, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
| | - Helen Marfan
- Faculty of Medicine, The University of Queensland, Herston, QLD, Australia.,Genetic Health Queensland, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
| | - Rachel Susman
- Faculty of Medicine, The University of Queensland, Herston, QLD, Australia.,Genetic Health Queensland, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
| | - Jan Wakeling
- Genetic Health Queensland, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
| | - Sonja Gustafson
- Department of Medical Imaging, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.,Department of Medical Imaging, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
| | - Simon Wood
- Faculty of Medicine, The University of Queensland, Herston, QLD, Australia.,Department of Urology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
| | - Andrew John Mallett
- Faculty of Medicine, The University of Queensland, Herston, QLD, Australia.,Department of Renal Medicine, Townsville University Hospital, Douglas, QLD, Australia.,College of Medicine and Dentistry, James Cook University, Douglas, QLD, Australia.,Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD, Australia
| |
Collapse
|
35
|
Benemerito I, Griffiths W, Allsopp J, Furnass W, Bhattacharya P, Li X, Marzo A, Wood S, Viceconti M, Narracott A. Delivering computationally-intensive digital patient applications to the clinic: An exemplar solution to predict femoral bone strength from CT data. Comput Methods Programs Biomed 2021; 208:106200. [PMID: 34107372 DOI: 10.1016/j.cmpb.2021.106200] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Accepted: 05/19/2021] [Indexed: 06/12/2023]
Abstract
BACKGROUND AND OBJECTIVE Whilst fragility hip fractures commonly affect elderly people, often causing permanent disability or death, they are rarely addressed in advance through preventive techniques. Quantification of bone strength can help to identify subjects at risk, thus reducing the incidence of fractures in the population. In recent years, researchers have shown that finite element models (FEMs) of the hip joint, derived from computed tomography (CT) images, can predict bone strength more accurately than other techniques currently used in the clinic. The specialised hardware and trained personnel required to perform such analyses, however, limits the widespread adoption of FEMs in clinical contexts. In this manuscript we present CT2S (Computed Tomography To Strength), a system developed in collaboration between The University of Sheffield and Sheffield Teaching Hospitals, designed to streamline access to this complex workflow for clinical end-users. METHODS The system relies on XNAT and makes use of custom apps based on open source software. Available through a website, it allows doctors in the healthcare environment to benefit from FE based bone strength estimation without being exposed to the technical aspects, which are concealed behind a user-friendly interface. Clinicians request the analysis of CT scans of a patient through the website. Using XNAT functionality, the anonymised images are automatically transferred to the University research facility, where an operator processes them and estimates the bone strength through FEM using a combination of open source and commercial software. Following the analysis, the doctor is provided with the results in a structured report. RESULTS The platform, currently available for research purposes, has been deployed and fully tested in Sheffield, UK. The entire analysis requires processing times ranging from 3.5 to 8 h, depending on the available computational power. CONCLUSIONS The short processing time makes the system compatible with current clinical workflows. The use of open source software and the accurate description of the workflow given here facilitates the deployment in other centres.
Collapse
Affiliation(s)
- I Benemerito
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Mechanical Engineering, The University of Sheffield, UK.
| | - W Griffiths
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Mechanical Engineering, The University of Sheffield, UK
| | - J Allsopp
- Sheffield Teaching Hospital Foundation Trust, Sheffield, UK
| | - W Furnass
- Department of Computer Science, The University of Sheffield, UK
| | - P Bhattacharya
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Mechanical Engineering, The University of Sheffield, UK
| | - X Li
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Mechanical Engineering, The University of Sheffield, UK
| | - A Marzo
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Mechanical Engineering, The University of Sheffield, UK
| | - S Wood
- Sheffield Teaching Hospital Foundation Trust, Sheffield, UK
| | - M Viceconti
- Department of Industrial Engineering, Alma Mater Studiorium, University of Bologna, Italy; Medical Technology Lab, IRCSS Istituto Ortopedico Rizzoli, Bologna, Italy
| | - A Narracott
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Infection, Immunity & Cardiovascular Disease, The University of Sheffield, UK
| |
Collapse
|
36
|
Wyborn C, Montana J, Kalas N, Clement S, Davila F, Knowles N, Louder E, Balan M, Chambers J, Christel L, Forsyth T, Henderson G, Izquierdo Tort S, Lim M, Martinez‐Harms MJ, Merçon J, Nuesiri E, Pereira L, Pilbeam V, Turnhout E, Wood S, Ryan M. An agenda for research and action toward diverse and just futures for life on Earth. Conserv Biol 2021; 35:1086-1097. [PMID: 33244774 PMCID: PMC8359367 DOI: 10.1111/cobi.13671] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 10/14/2020] [Accepted: 11/20/2020] [Indexed: 06/11/2023]
Abstract
Decades of research and policy interventions on biodiversity have insufficiently addressed the dual issues of biodiversity degradation and social justice. New approaches are therefore needed. We devised a research and action agenda that calls for a collective task of revisiting biodiversity toward the goal of sustaining diverse and just futures for life on Earth. Revisiting biodiversity involves critically reflecting on past and present research, policy, and practice concerning biodiversity to inspire creative thinking about the future. The agenda was developed through a 2-year dialogue process that involved close to 300 experts from diverse disciplines and locations. This process was informed by social science insights that show biodiversity research and action is underpinned by choices about how problems are conceptualized. Recognizing knowledge, action, and ethics as inseparable, we synthesized a set of principles that help navigate the task of revisiting biodiversity. The agenda articulates 4 thematic areas for future research. First, researchers need to revisit biodiversity narratives by challenging conceptualizations that exclude diversity and entrench the separation of humans, cultures, economies, and societies from nature. Second, researchers should focus on the relationships between the Anthropocene, biodiversity, and culture by considering humanity and biodiversity as tied together in specific contexts. Third, researchers should focus on nature and economies by better accounting for the interacting structures of economic and financial systems as core drivers of biodiversity loss. Finally, researchers should enable transformative biodiversity research and action by reconfiguring relationships between human and nonhuman communities in and through science, policy, and practice. Revisiting biodiversity necessitates a renewed focus on dialogue among biodiversity communities and beyond that critically reflects on the past to channel research and action toward fostering just and diverse futures for human and nonhuman life on Earth.
Collapse
Affiliation(s)
- C. Wyborn
- Luc Hoffmann InstituteIUCN Conservation CentreRue Mauverney 28Gland1196Switzerland
- Institute for Water Futures, Fenner School of Environment and SocietyAustralian National UniversityCanberraACT0200Australia
| | - J. Montana
- School of Geography and the EnvironmentUniversity of OxfordSouth Parks RoadOxfordOX1 3QYU.K.
| | - N. Kalas
- Department of Environmental Systems ScienceETH ZürichUniversitätstrasse 8‐22Zürich8092Switzerland
| | - S. Clement
- Geography and PlanningUniversity of LiverpoolLiverpoolL69 3BXU.K.
| | - F. Davila
- Institute for Sustainable FuturesUniversity of Technology Sydney253 Jones StreetUltimoNSW2007Australia
| | - N. Knowles
- Department of Geography and Environmental ManagementUniversity of Waterloo200 University Ave WWaterlooONN2L 3G1Canada
| | - E. Louder
- School of Geography and DevelopmentUniversity of ArizonaENR2 Building, South 4th floor 1064 E. Lowell StreetTucsonAZ85721U.S.A.
| | - M. Balan
- The Forest WayNo 8, 2nd St, D P Nagar, KotturpuramChennaiTamil Nadu600085India
| | - J. Chambers
- Forest and Nature Conservation Policy GroupWageningen UniversityP.O. Box 47Wageningen6700 AAThe Netherlands
| | - L. Christel
- School of Politics and Government (EPyG)National University of San MartinAvenida 25 de Mayo 1021San MartínProvincia de Buenos Aires1650Argentina
| | - T. Forsyth
- Department of International DevelopmentLondon School of Economics and Political ScienceHoughton StreetLondonWC2A 2AEU.K
| | - G. Henderson
- Harry Ransom CenterThe University of Texas at AustinP.O. Drawer 7219, 300 W 21st StreetAustinTX78712U.S.A.
| | - S. Izquierdo Tort
- Institut des Sciences de la Forêt TempéréeUniversité du Québec en Outaouais58 rue PrincipaleRiponQCJ0V 1V0Canada
- Natura y Ecosistemas Mexicanos A.C.Plaza San Jacinto 23D, San Ángel, Álvaro ObregónMexico City01000Mexico
| | - M. Lim
- Centre for Environmental Law, Macquarie Law SchoolMacquarie University6 First WalkSydneyNSW2109Australia
| | - M. J. Martinez‐Harms
- Center for Applied Ecology and Sustainability (CAPES)Pontificia Universidad Católica de ChileSantiago, Avd. Libertador Bernardo O'Higgins 340SantiagoChile
| | - J. Merçon
- Instituto de Investigaciones en EducasiónUniversidad VeracruzanaPaseo 112, Nuevo JalapaXalapa‐Enríquez91193Mexico
| | - E. Nuesiri
- Social Science FacultyAfrican Leadership University (ALU)Powder Mill RoadPamplemousses21001Mauritius
| | - L. Pereira
- Stockholm Resilience CentreStockholm UniversityKräftriket 2BStockholmSE‐10691Sweden
- Copernicus Institute of Sustainable DevelopmentUtrecht UniversityPrincetonlaan 8aUtrecht3584 CBThe Netherlands
- Centre for Complex Systems in TransitionStellenbosch University19 Jonkershoek Rd, MostertsdriftStellenbosch7600South Africa
| | - V. Pilbeam
- Clear Horizon Consulting132B Gwynne StCremorneVIC3121Australia
| | - E. Turnhout
- Forest and Nature Conservation Policy GroupWageningen UniversityP.O. Box 47Wageningen6700 AAThe Netherlands
| | - S. Wood
- Future Earth1250 Guy St, MontrealQuebecONH3H 2L3Canada
| | - M. Ryan
- Luc Hoffmann InstituteIUCN Conservation CentreRue Mauverney 28Gland1196Switzerland
| |
Collapse
|
37
|
Wyborn C, Montana J, Kalas N, Clement S, Davila F, Knowles N, Louder E, Balan M, Chambers J, Christel L, Forsyth T, Henderson G, Izquierdo Tort S, Lim M, Martinez-Harms MJ, Merçon J, Nuesiri E, Pereira L, Pilbeam V, Turnhout E, Wood S, Ryan M. An agenda for research and action toward diverse and just futures for life on Earth. Conserv Biol 2021; 35:1086-1097. [PMID: 33244774 DOI: 10.13140/rg.2.2.12086.52804/2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 10/14/2020] [Accepted: 11/20/2020] [Indexed: 05/18/2023]
Abstract
Decades of research and policy interventions on biodiversity have insufficiently addressed the dual issues of biodiversity degradation and social justice. New approaches are therefore needed. We devised a research and action agenda that calls for a collective task of revisiting biodiversity toward the goal of sustaining diverse and just futures for life on Earth. Revisiting biodiversity involves critically reflecting on past and present research, policy, and practice concerning biodiversity to inspire creative thinking about the future. The agenda was developed through a 2-year dialogue process that involved close to 300 experts from diverse disciplines and locations. This process was informed by social science insights that show biodiversity research and action is underpinned by choices about how problems are conceptualized. Recognizing knowledge, action, and ethics as inseparable, we synthesized a set of principles that help navigate the task of revisiting biodiversity. The agenda articulates 4 thematic areas for future research. First, researchers need to revisit biodiversity narratives by challenging conceptualizations that exclude diversity and entrench the separation of humans, cultures, economies, and societies from nature. Second, researchers should focus on the relationships between the Anthropocene, biodiversity, and culture by considering humanity and biodiversity as tied together in specific contexts. Third, researchers should focus on nature and economies by better accounting for the interacting structures of economic and financial systems as core drivers of biodiversity loss. Finally, researchers should enable transformative biodiversity research and action by reconfiguring relationships between human and nonhuman communities in and through science, policy, and practice. Revisiting biodiversity necessitates a renewed focus on dialogue among biodiversity communities and beyond that critically reflects on the past to channel research and action toward fostering just and diverse futures for human and nonhuman life on Earth.
Collapse
Affiliation(s)
- C Wyborn
- Luc Hoffmann Institute, IUCN Conservation Centre, Rue Mauverney 28, Gland, 1196, Switzerland
- Institute for Water Futures, Fenner School of Environment and Society, Australian National University, Canberra, ACT, 0200, Australia
| | - J Montana
- School of Geography and the Environment, University of Oxford, South Parks Road, Oxford, OX1 3QY, U.K
| | - N Kalas
- Department of Environmental Systems Science, ETH Zürich, Universitätstrasse 8-22, Zürich, 8092, Switzerland
| | - S Clement
- Geography and Planning, University of Liverpool, Liverpool, L69 3BX, U.K
| | - F Davila
- Institute for Sustainable Futures, University of Technology Sydney, 253 Jones Street, Ultimo, NSW, 2007, Australia
| | - N Knowles
- Department of Geography and Environmental Management, University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada
| | - E Louder
- School of Geography and Development, University of Arizona, ENR2 Building, South 4th floor 1064 E. Lowell Street, Tucson, AZ, 85721, U.S.A
| | - M Balan
- The Forest Way, No 8, 2nd St, D P Nagar, Kotturpuram, Chennai, Tamil Nadu, 600085, India
| | - J Chambers
- Forest and Nature Conservation Policy Group, Wageningen University, P.O. Box 47, Wageningen, 6700 AA, The Netherlands
| | - L Christel
- School of Politics and Government (EPyG), National University of San Martin, Avenida 25 de Mayo 1021, San Martín, Provincia de Buenos Aires, 1650, Argentina
| | - T Forsyth
- Department of International Development, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, U.K
| | - G Henderson
- Harry Ransom Center, The University of Texas at Austin, P.O. Drawer 7219, 300 W 21st Street, Austin, TX, 78712, U.S.A
| | - S Izquierdo Tort
- Institut des Sciences de la Forêt Tempérée, Université du Québec en Outaouais, 58 rue Principale, Ripon, QC, J0V 1V0, Canada
- Natura y Ecosistemas Mexicanos A.C., Plaza San Jacinto 23D, San Ángel, Álvaro Obregón, Mexico City, 01000, Mexico
| | - M Lim
- Centre for Environmental Law, Macquarie Law School, Macquarie University, 6 First Walk, Sydney, NSW, 2109, Australia
| | - M J Martinez-Harms
- Center for Applied Ecology and Sustainability (CAPES), Pontificia Universidad Católica de Chile, Santiago, Avd. Libertador Bernardo O'Higgins 340, Santiago, Chile
| | - J Merçon
- Instituto de Investigaciones en Educasión, Universidad Veracruzana, Paseo 112, Nuevo Jalapa, Xalapa-Enríquez, 91193, Mexico
| | - E Nuesiri
- Social Science Faculty, African Leadership University (ALU), Powder Mill Road, Pamplemousses, 21001, Mauritius
| | - L Pereira
- Stockholm Resilience Centre, Stockholm University, Kräftriket 2B, Stockholm, SE-10691, Sweden
- Copernicus Institute of Sustainable Development, Utrecht University, Princetonlaan 8a, Utrecht, 3584 CB, The Netherlands
- Centre for Complex Systems in Transition, Stellenbosch University, 19 Jonkershoek Rd, Mostertsdrift, Stellenbosch, 7600, South Africa
| | - V Pilbeam
- Clear Horizon Consulting, 132B Gwynne St, Cremorne, VIC, 3121, Australia
| | - E Turnhout
- Forest and Nature Conservation Policy Group, Wageningen University, P.O. Box 47, Wageningen, 6700 AA, The Netherlands
| | - S Wood
- Future Earth, 1250 Guy St, Montreal, Quebec, ON, H3H 2L3, Canada
| | - M Ryan
- Luc Hoffmann Institute, IUCN Conservation Centre, Rue Mauverney 28, Gland, 1196, Switzerland
| |
Collapse
|
38
|
Rhee H, Navaratnam A, Oleinikova I, Gilroy D, Scuderi Y, Heathcote P, Nguyen T, Wood S, Ho KKY. A Novel Liver-targeted Testosterone Therapy for Sarcopenia in Androgen Deprived Men With Prostate Cancer. J Endocr Soc 2021; 5:bvab116. [PMID: 34308090 PMCID: PMC8294688 DOI: 10.1210/jendso/bvab116] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Indexed: 12/25/2022] Open
Abstract
Objective Androgen deprivation therapy (ADT) reduces muscle and bone mass, increasing frailty in men with prostate cancer. The liver mediates the whole body anabolic effects of testosterone. Based on first-pass metabolism, liver-targeted testosterone treatment (LTTT) entails oral delivery of a small dose of testosterone that does not raise peripheral blood testosterone levels. LTTT reduces blood urea and stimulates protein anabolism in hypogonadal men and postmenopausal women. We investigated whether LTTT prevents loss of lean and bone mass during ADT. Method A 6-month, double-blind, placebo-controlled study of testosterone 40 mg/day in 50 men. Primary outcome measures were lean mass and bone mineral content (BMC). Testosterone, urea and prostate-specific antigen (PSA) were monitored. Patients were withdrawn if PSA exceeded 4 ng/mL. Results 42 patients completed the study. Mean (95% CI) testosterone rose during LTTT but not placebo treatment [∆ 2.2 (1.3-3.0) vs -0.7 (-1.5 to 0.2) nmol/L; P < 0.01]. Mean PSA level did not change significantly during either treatment. Blood urea fell [∆ -0.4 (-0.9 to -0.1) mmol/L] during LTTT but not placebo [∆ 0.05 (-0.8 to 0.9) mmol/L]. BMC [∆ 49 (5 to 93) g; P < 0.02] and lean mass [∆ 0.8 (-0.1 to 1.7) kg; P = 0.04) increased compared to placebo. Five patients on LTTT withdrew from increased PSA levels, all returning to baseline levels. Conclusion LTTT shows promise as a simple therapy for preventing sarcopenia and bone loss during ADT. LTTT may induce reversible PSA rise in some patients. Further studies are required to optimize LTTT dose in ADT. LTTT has potential application in other catabolic states in men and women.
Collapse
Affiliation(s)
- Handoo Rhee
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia.,Faculty of Medicine, the University of Queensland, Brisbane, Australia
| | - Anojan Navaratnam
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia
| | - Irina Oleinikova
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia
| | - Deborah Gilroy
- Department of Endocrinology, Princess Alexandra Hospital, Brisbane, Australia
| | - Yolanda Scuderi
- Department of Pharmacy, Princess Alexandra Hospital, Brisbane, Australia
| | - Peter Heathcote
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia
| | - Tuan Nguyen
- School of Biomedical Engineering, University of Technology, Sydney, Australia.,Garvan Institute of Medical Research and the Faculty of Medicine, the University of New South Wales, Sydney, Australia
| | - Simon Wood
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia.,Faculty of Medicine, the University of Queensland, Brisbane, Australia
| | - Ken K Y Ho
- Department of Endocrinology, Princess Alexandra Hospital, Brisbane, Australia.,The Translational Research Institute, Brisbane, Australia.,Faculty of Medicine, the University of Queensland, Brisbane, Australia.,Garvan Institute of Medical Research and the Faculty of Medicine, the University of New South Wales, Sydney, Australia
| |
Collapse
|
39
|
Abstract
The skeleton is the most common site of secondary disease in breast cancer and prostate cancer, with up to 80% of patients with advanced disease developing bone metastases (BM). The proportion is also substantial in advanced lung cancer (20%-40%). Because of the high prevalence of cancers of the breast, prostate and lung, these cancers account for more than 80% of cases of metastatic bone disease occurring in solid tumours. Metastatic bone disease is associated with greatly increased bone resorption by osteoclasts, leading to moderate to severe pain and other skeletal complications, with major impact on quality of life (QoL). Skeletal Related Events (SREs) have been defined as: pathological long bone or vertebral fractures; spinal cord compression; need for radiation for pain relief or to prevent fracture/spinal cord compression, need for surgery to bone and hypercalcaemia. More recently, Symptomatic Skeletal Events (SSEs) have been defined to monitor QoL. Although there are currently no curative treatments for metastatic bone disease, patients with breast or prostate cancer and BM are now surviving for several years and sometimes longer, and prevention of SREs is the key aim to optimization of QoL. Since their discovery 50 years ago and their introduction more than 30 years ago into the field of metastatic bone disease, a range of oral and intravenous bisphosphonate drugs have made a major contribution to prevention of SREs. Large trials have clearly demonstrated the clinical value of different bisphosphonate-based drugs (including the oral drugs ibandronate and clodronate and intravenous agents such as zoledronate and pamidronate), in treatment of hypercalcaemia of malignancy and the reduction of SREs and SSEs in a range of cancers. Despite the success of denosumab in reducing osteolysis, bisphosphonates also remain mainstay drugs for treatment of metastatic bone disease. Recognizing the 50th Anniversary of the discovery of bisphosphonates, this review focuses on their continuing value in BM treatment and their future potential, for example in providing a bone-targeting vehicle for cytotoxic drugs.
Collapse
Affiliation(s)
- S D'Oronzo
- Medical Oncology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, P.za Giulio Cesare, 11, 70124 Bari, Italy
| | - S Wood
- Department of Oncology and Metabolism, The Medical School, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK.
| | - J E Brown
- Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, University of Sheffield, Weston Park Hospital, Whitham Rd, Broomhill, Sheffield S10 2SJ, UK
| |
Collapse
|
40
|
Lopez‐Girona A, Groocock L, Mo Z, Narla RK, Janardhanan P, Wood S, Mendy D, Barnes L, Peng S, Jankeel D, Fontanillo C, Carrancio S, Hansen J. CC‐99282 IS A NOVEL CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT WITH POTENT AND BROAD ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). Hematol Oncol 2021. [DOI: 10.1002/hon.144_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- A Lopez‐Girona
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - L Groocock
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - Z Mo
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - R. K Narla
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - P Janardhanan
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - S Wood
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - D Mendy
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - L Barnes
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - S Peng
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - D Jankeel
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - C Fontanillo
- Bristol Myers Squibb, Informatics and Predictive Sciences, Princeton New Jersey USA
| | - S Carrancio
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - J Hansen
- Bristol Myers Squibb, Small Molecule Drug Discovery, Princeton New Jersey USA
| |
Collapse
|
41
|
Pryor D, Bressel M, Lawrentschuk N, Tran B, Mooi J, Lewin J, Azad A, Colyer D, Neha N, Shaw M, Chander S, Neeson P, Moon D, Cuff K, Wood S, Murphy DG, Sandhu S, Loi S, Siva S. A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. Contemp Clin Trials Commun 2021; 21:100703. [PMID: 33490707 PMCID: PMC7807247 DOI: 10.1016/j.conctc.2021.100703] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2020] [Revised: 09/27/2020] [Accepted: 01/01/2021] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND The management of oligometastatic clear cell renal cell carcinoma (ccRCC) varies widely, ranging from observation to resection or systemic therapies. Prolonged survival has been observed following resection or stereotactic ablative body radiotherapy (SABR). Immunotherapy combinations have shown survival benefits, however, toxicity is higher than that for monotherapy and complete response rates remain less than 10%. The combination of effective local therapies in conjunction with immunotherapy may provide more durable control and pre-clinical models have suggested a synergistic immune-priming effect of SABR. OBJECTIVES and Methods: RAPPORT is a prospective, single arm, phase I/II study assessing the safety, efficacy and biological effects of single fraction SABR followed by pembrolizumab for oligometastatic ccRCC. The study will include 30 patients with histological confirmed ccRCC and 1-5 oligometastases, one or more of which must be suitable for SABR. Patients can have received prior systemic therapy but not prior immunotherapy. A single 20Gy of SABR is followed 5 days later by 8 cycles of 200 mg pembrolizumab, every 3 weeks. Adverse events are recorded using CTCAE V4.03 and tumour response evaluated by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1). Tumour tissue and peripheral blood samples will be collected pre-, during and post-treatment to assess longitudinal changes in immune subsets. OUTCOMES AND SIGNIFICANCE The RAPPORT study will provide important safety and early efficacy data on the combination of SABR and pembrolizumab in oligometastatic ccRCC and will provide an insight into the underlying biological effects of combination therapy. TRIAL REGISTRATION clinicaltrials.gov ID NCT02855203.
Collapse
Affiliation(s)
- David Pryor
- Princess Alexandra Hospital, Brisbane, Australia
- University of Queensland, Brisbane, Australia
| | | | - Nathan Lawrentschuk
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| | - Ben Tran
- Peter MacCallum Cancer Centre, Melbourne, Australia
- Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
| | - Jennifer Mooi
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| | - Jeremy Lewin
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| | - Arun Azad
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| | | | - Nitika Neha
- Peter MacCallum Cancer Centre, Melbourne, Australia
| | - Mark Shaw
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| | - Sarat Chander
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| | - Paul Neeson
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| | - Daniel Moon
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| | - Katharine Cuff
- Princess Alexandra Hospital, Brisbane, Australia
- University of Queensland, Brisbane, Australia
| | - Simon Wood
- Princess Alexandra Hospital, Brisbane, Australia
- University of Queensland, Brisbane, Australia
| | - Declan G. Murphy
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| | - Shahneen Sandhu
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| | - Sherene Loi
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| | - Shankar Siva
- Peter MacCallum Cancer Centre, Melbourne, Australia
- University of Melbourne, Parkville, Australia
| |
Collapse
|
42
|
Siva S, Bressel M, Wood S, Shaw M, Loi S, Sandhu SK, Tran B, Azad A, Lewin JH, Cuff K, Neha N, Colyer D, Neeson PJ, Liu H, Chander S, Moon D, Goad J, Murphy DG, Lawrentschuk N, Pryor D. Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.6_suppl.277] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
277 Background: Pembrolizumab monotherapy, whilst not standard of care, has demonstrated efficacy in clear cell renal cell carcinoma (ccRCC). The first-line KEYNOTE-427 study demonstrated an overall response rate (ORR) of 34%, and a median progression-free survival (PFS) of 7.1 mo (McDermott D et al. J Clin Oncol 2020; 38:S15; 5069-5069). Stereotactic ablative body radiotherapy (SABR) is an option for oligometastatic ccRCC, but patients often develop distant progression or relapse within irradiated sites. The RAPPORT study (NCT02855203) was a multi-institutional single arm, phase I/II study evaluating safety and efficacy of SABR and pembrolizumab. Methods: Patients with up to 2 lines of prior systemic therapy with 1-5 oligometastases from ccRCC were eligible. A single fraction of 20Gy SABR to all metastatic sites was given (or 10 fractions of 3 Gy of conventional radiotherapy [CRT] if SABR was not feasible), followed by pembrolizumab 200mg administered Q3W for 8 cycles. The primary objective was safety (CTCAEv4.03), with secondary key objectives of efficacy (RECIST1.1) by disease control rate (DCR), defined as complete response (CR), partial response (PR) or stable disease for at least 6 months, ORR, PFS and overall survival (OS). Results: Thirty patients were enrolled and received protocol treatment. The median follow-up was was 2.3 years. The median age was 62 (range 47-80) years, 23 patients (77%) were male. Twenty-three patients (77%) were treatment naïve, 1 patient (3%) had a prior interleukin-2 therapy and 6 patients (20%) had a prior tyrosine kinase inhibitor. Nine patients (30%) had prior metastasectomy. Eighty-three oligometastases were treated (median of 3 per patient), of which 64 (77%) received SABR, and 19 (23%) received CRT. There were 8 adrenal, 11 bone, 43 lung, 12 lymph node and 9 soft tissue metastases irradiated. Four patients (13% [95%CI: 4-31%]) had one or more grade 3 treatment-related AE: Pneumonitis (n=2), dyspnoea (n=1) and elevated ALP/ALT (n=1). There were no grade 4 or 5 AEs. All eight cycles of pembrolizumab were completed by 24 (80%) patients. DCR was 83% (95%CI: 65-94%). ORRs are tabulated below. Median PFS was 15.6 mo. Estimated 1 and 2-year OS was 90% (95%CI: 72-97%) and 74% (95%CI: 53-87%), respectively, while PFS was 60% (95%CI: 40-75%) and 45% (95%CI: 27-62%), respectively. Freedom from local progression at 2-years was 92% (95%CI: 80-97%). Conclusions: The combination of SABR and pembrolizumab in oligometastatic renal cell carcinoma is well tolerated with excellent local control. Durable responses and encouraging PFS were observed with this approach, which warrants further investigation. Clinical trial information: NCT02855203 . [Table: see text]
Collapse
Affiliation(s)
- Shankar Siva
- Peter MacCallum Cancer Center, Melbourne, VIC, Australia
| | | | - Simon Wood
- Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - Mark Shaw
- Peter MacCallum Cancer Center, Melbourne, VIC, Australia
| | - Sherene Loi
- Peter MacCallum Cancer Center, Melbourne, VIC, Australia
| | | | - Ben Tran
- Peter MacCallum Cancer Center, Melbourne, VIC, Australia
| | - Arun Azad
- Peter MacCallum Cancer Center, Melbourne, VIC, Australia
| | | | | | - Nitika Neha
- Peter MacCallum Cancer Center, Melbourne, VIC, Australia
| | - Duncan Colyer
- Peter MacCallum Cancer Center, Melbourne, VIC, Australia
| | - Paul J. Neeson
- Cancer Immunology Research, Peter MacCallum Cancer Center, Melbourne, VIC, Australia
| | - Howard Liu
- Princess Alexandra Hospital, Brisbane, Australia
| | - Sarat Chander
- Peter MacCallum Cancer Center, Melbourne, VIC, Australia
| | - Daniel Moon
- The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
| | - Jeremy Goad
- Peter MacCallum Cancer Center, Melbourne, VIC, Australia
| | | | | | - David Pryor
- Princess Alexandra Hospital, Brisbane, QLD, Australia
| |
Collapse
|
43
|
Clark EM, Garner J, Wood S. Commercial weight management programmes for patients living with overweight or obesity prior to elective orthopaedic surgery: an evidence review. J Public Health (Oxf) 2021; 44:417-427. [PMID: 33550385 DOI: 10.1093/pubmed/fdaa253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 11/18/2020] [Accepted: 12/11/2020] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Increased body mass index is associated with increased operative risk during elective joint replacement surgery. Commercial weight management programmes are designed to achieve weight loss. It is not known whether commercial weight management programmes are effective at achieving weight loss in patients awaiting planned hip or knee replacement surgery, or whether achieving significant planned weight loss prior to surgery is associated with changes in surgical outcome. METHODS A systematic literature search of seven databases was conducted. Reference lists and grey literature were searched, including commercial weight management programme and medical association websites. Four relevant primary interventional studies were identified. RESULTS There is weak, low-quality evidence from four small studies, of which three demonstrated that commercial weight management programmes initiated between 3 and 6 months prior to elective joint replacement surgery are associated with a statistically significant weight loss and body mass index reduction. There is a weak evidence from two studies that peri- and post-operative complications are similar between control and commercial weight management programme groups. CONCLUSION There is a paucity of studies investigating commercial weight management programmes aiming to reduce weight in patients living with overweight or obesity awaiting total joint replacement. Further, high-quality research is urgently needed.
Collapse
Affiliation(s)
- E M Clark
- Public Health Wales, Capital Quarter 2, Cardiff, CF10 4BZ, Wales
| | - J Garner
- Public Health Wales, Capital Quarter 2, Cardiff, CF10 4BZ, Wales
| | - S Wood
- Public Health Wales, Cardiff, CF14 4HH, Wales
| |
Collapse
|
44
|
Bubak M, Czechowicz K, Gubała T, Hose DR, Kasztelnik M, Malawski M, Meizner J, Nowakowski P, Wood S. The EurValve model execution environment. Interface Focus 2021; 11:20200006. [PMID: 33343876 DOI: 10.1098/rsfs.2020.0006] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/23/2020] [Indexed: 01/14/2023] Open
Abstract
The goal of this paper is to present a dedicated high-performance computing (HPC) infrastructure which is used in the development of a so-called reduced-order model (ROM) for simulating the outcomes of interventional procedures which are contemplated in the treatment of valvular heart conditions. Following a brief introduction to the problem, the paper presents the design of a model execution environment, in which representative cases can be simulated and the parameters of the ROM fine-tuned to enable subsequent deployment of a decision support system without further need for HPC. The presentation of the system is followed by information concerning its use in processing specific patient cases in the context of the EurValve international collaboration.
Collapse
Affiliation(s)
- M Bubak
- Department of Computer Science, AGH University of Science and Technology, Kraków, Poland.,ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - K Czechowicz
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - T Gubała
- ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - D R Hose
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - M Kasztelnik
- ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - M Malawski
- Department of Computer Science, AGH University of Science and Technology, Kraków, Poland.,ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - J Meizner
- ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - P Nowakowski
- ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - S Wood
- Medical Physics and Clinical Engineering, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| |
Collapse
|
45
|
Delaigle A, Wood S. Report of the Editors—2020. J R Stat Soc Series B Stat Methodol 2020. [DOI: 10.1111/rssb.12408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
46
|
Sulistyoningrum D, Green T, Palmer D, Sullivan T, Wood S, Makrides M, Skubisz M, Best KP. Study protocol for a randomised controlled trial evaluating the effect of folic acid supplementation beyond the first trimester on maternal plasma unmetabolised folic acid in late gestation. BMJ Open 2020; 10:e040416. [PMID: 33199423 PMCID: PMC7670954 DOI: 10.1136/bmjopen-2020-040416] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
INTRODUCTION Taking folic acid containing supplements prior to and during early pregnancy reduces the risk of neural tube defects. Neural tube defects occur prior to 28 days postconception, after which, there is no proven benefit of continuing to take folic acid. However, many women continue to take folic acid containing supplements throughout the pregnancy. At higher intakes, folic acid is not converted to its active form and accumulates in circulation as unmetabolised folic acid (UMFA). Recently, concerns have been raised about possible links between late gestation folic acid supplementation and childhood allergy, metabolic disease and autism spectrum disorders. We aim to determine if removing folic acid from prenatal micronutrient supplements after 12 weeks gestation reduces circulating levels of maternal UMFA at 36 weeks gestation. METHODS AND ANALYSIS This is a parallel-design, double-blinded randomised controlled trial. Women ≥12 and <16 weeks' gestation with a singleton pregnancy and able to give informed consent are eligible to participate. Women (n=100; 50 per group) will be randomised to receive either a micronutrient supplement containing 0.8 mg of folic acid or a micronutrient supplement without folic acid daily from enrolment until delivery. The primary outcome is plasma UMFA concentration at 36 weeks gestation. Secondary outcomes include red blood cell folate and total plasma folate concentration. We will assess whether there is a difference in mean UMFA levels at 36 weeks gestation between groups using linear regression with adjustment for baseline UMFA levels and gestational age at trial entry. The treatment effect will be described as a mean difference with 95% CI. ETHICS AND DISSEMINATION Ethical approval has been granted from the Women's and Children's Health Network Research Ethics Committee (HREC/19/WCHN/018). The results of this trial will be presented at scientific conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER ACTRN12619001511123.
Collapse
Affiliation(s)
- Dian Sulistyoningrum
- SAHMRI Women and Kids Theme, South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia
- Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
| | - Tim Green
- SAHMRI Women and Kids Theme, South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia
- Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
| | - Debbie Palmer
- Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia
| | - Thomas Sullivan
- SAHMRI Women and Kids Theme, South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia
- Faculty of Health and Medical Sciences, School of Public Health, The University of Adelaide, Adelaide, South Australia, Australia
| | - Simon Wood
- Faculty of Science and Engineering, Curtin University, Perth, West Australia, Australia
- Faculty of Land and Food Systems, University of British Columbia, Vancouver, British Columbia, Canada
| | - Maria Makrides
- SAHMRI Women and Kids Theme, South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia
- Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
| | - Monika Skubisz
- SAHMRI Women and Kids Theme, South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia
- Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
| | - Karen P Best
- SAHMRI Women and Kids Theme, South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia
- Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
| |
Collapse
|
47
|
Protani MM, Joshi A, White V, Marco DJT, Neale RE, Coory MD, Giles GG, Bolton DM, Davis ID, Wood S, Jordan SJ. The role of renal mass biopsy in the management of small renal masses – patterns of use and surgeon opinion. Journal of Clinical Urology 2020. [DOI: 10.1177/2051415819894181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims: Renal mass biopsy (RMB) is advocated to improve management of small renal masses, however there is concern about its clinical utility. This study aimed to elicit opinions about the role of RMB in small renal mass management from surgeons managing renal cell carcinomas (RCC), and examine the frequency of pre-treatment biopsy in those with RCC. Methods: All surgeons in two Australian states (Queensland: n = 59 and Victoria: n = 108) who performed nephrectomies for RCC in 2012/2013 were sent questionnaires to ascertain views about RMB. Response rates were 54% for Queensland surgeons and 38% for Victorian surgeons. We used medical records data from RCC patients to determine RMB frequency. Results: Most Queensland (81%) and Victorian (59%) surgeons indicated they rarely requested RMB; however 34% of Victorians reported often requesting RMB, compared with no Queensland surgeons. This was consistent with medical records data: 17.6% of Victorian patients with T1a tumours received RMB versus 6.7% of Queensland patients ( p < 0.001). Surgeons’ principal concerns regarding RMB related to sampling reliability (90%) and/or histopathological interpretation (76%). Conclusions: Most surgeons report infrequent use of RMB for small renal masses, however we observed practice variation. The principal reasons for infrequent use were concerns about sampling reliability and histopathological interpretation, which may be valid in regions with less access to interventional radiologists and uropathologists. Further evidence is required to define patient groups for whom biopsy results will alter management. Level of evidence: Not applicable for this multicentre audit.
Collapse
Affiliation(s)
- Melinda M Protani
- School of Public Health, The University of Queensland, Herston, Australia
- QIMR Berghofer Medical Research Institute, Herston, Australia
| | - Andre Joshi
- QIMR Berghofer Medical Research Institute, Herston, Australia
- Princess Alexandra Hospital, Brisbane, Queensland, Australia
- Translational Research Institute, Brisbane, Australia
| | - Victoria White
- Cancer Council Victoria, Melbourne, Australia
- Deakin University, Geelong, Australia
| | - David JT Marco
- University of Melbourne, Melbourne, Australia
- Centre for Palliative Care, St Vincent’s Hospital, Melbourne, Australia
| | - Rachel E Neale
- School of Public Health, The University of Queensland, Herston, Australia
- QIMR Berghofer Medical Research Institute, Herston, Australia
| | | | - Graham G Giles
- Cancer Council Victoria, Melbourne, Australia
- University of Melbourne, Melbourne, Australia
| | - Damien M Bolton
- University of Melbourne, Melbourne, Australia
- Austin Health, Melbourne, Australia
| | - Ian D Davis
- Monash University Eastern Health Clinical School, Box Hill, Melbourne, Australia
- Eastern Health, Box Hill, Melbourne, Australia
| | - Simon Wood
- Princess Alexandra Hospital, Brisbane, Queensland, Australia
- Translational Research Institute, Brisbane, Australia
| | - Susan J Jordan
- School of Public Health, The University of Queensland, Herston, Australia
- QIMR Berghofer Medical Research Institute, Herston, Australia
| |
Collapse
|
48
|
Tee HS, Waite D, Payne L, Middleditch M, Wood S, Handley KM. Tools for successful proliferation: diverse strategies of nutrient acquisition by a benthic cyanobacterium. ISME J 2020; 14:2164-2178. [PMID: 32424245 PMCID: PMC7367855 DOI: 10.1038/s41396-020-0676-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/22/2019] [Revised: 04/23/2020] [Accepted: 05/01/2020] [Indexed: 12/28/2022]
Abstract
Freshwater cyanobacterial blooms have increased worldwide, channeling organic carbon into these systems, and threatening animal health through the production of cyanotoxins. Both toxic and nontoxic Microcoleus proliferations usually occur when there are moderate concentrations of dissolved inorganic nitrogen, but when phosphorus is scarce. In order to understand how Microcoleus establishes thick biofilms (or mats) on riverbeds under phosphorus-limiting conditions, we collected Microcoleus-dominated biofilms over a 19-day proliferation event for proteogenomics. A single pair of nitrogen-dependent Microcoleus species were consistently present in relatively high abundance, although each followed a unique metabolic trajectory. Neither possessed anatoxin gene clusters, and only very low concentrations of anatoxins (~2 µg kg-1) were detected, likely originating from rarer Microcoleus species also present. Proteome allocations were dominated by photosynthesizing cyanobacteria and diatoms, and data indicate biomass was actively recycled by Bacteroidetes and Myxococcales. Microcoleus likely acquired nutrients throughout the proliferation event by uptake of nitrate, urea, and inorganic and organic phosphorus. Both species also harbored genes that could be used for inorganic phosphate solubilization with pyrroloquinoline quinone cofactors produced by cohabiting Proteobacteria. Results indicate that Microcoleus are equipped with diverse mechanisms for nitrogen and phosphorus acquisition, enabling them to proliferate and out-compete others in low-phosphorus waters.
Collapse
Affiliation(s)
- H S Tee
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - D Waite
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - L Payne
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - M Middleditch
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - S Wood
- Cawthron Institute, Nelson, New Zealand
| | - K M Handley
- School of Biological Sciences, University of Auckland, Auckland, New Zealand.
| |
Collapse
|
49
|
Wood S, Conrad D, Schwalbe N. Washington’s State Innovation Models (SIM) Project: Effects of Primary Care and Behavioral Health Integration on Participating Organizations. Health Serv Res 2020. [DOI: 10.1111/1475-6773.13380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Affiliation(s)
- S. Wood
- University of Washington Seattle WA United States
| | - D. Conrad
- University of Washington Seattle WA United States
| | - N. Schwalbe
- University of Washington Seattle WA United States
| |
Collapse
|
50
|
Contreras A, Raxworthy MJ, Wood S, Tronci G. Hydrolytic Degradability, Cell Tolerance and On-Demand Antibacterial Effect of Electrospun Photodynamically Active Fibres. Pharmaceutics 2020; 12:E711. [PMID: 32751391 PMCID: PMC7465204 DOI: 10.3390/pharmaceutics12080711] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Revised: 07/22/2020] [Accepted: 07/24/2020] [Indexed: 01/17/2023] Open
Abstract
Photodynamically active fibres (PAFs) are a novel class of stimulus-sensitive systems capable of triggering antibiotic-free antibacterial effect on-demand when exposed to light. Despite their relevance in infection control, however, the broad clinical applicability of PAFs has not yet been fully realised due to the limited control in fibrous microstructure, cell tolerance and antibacterial activity in the physiologic environment. We addressed this challenge by creating semicrystalline electrospun fibres with varying content of poly[(l-lactide)-co-(glycolide)] (PLGA), poly(ε-caprolactone) (PCL) and methylene blue (MB), whereby the effect of polymer morphology, fibre composition and photosensitiser (PS) uptake on wet state fibre behaviour and functions was studied. The presence of crystalline domains and PS-polymer secondary interactions proved key to accomplishing long-lasting fibrous microstructure, controlled mass loss and controlled MB release profiles (37 °C, pH 7.4, 8 weeks). PAFs with equivalent PLGA:PCL weight ratio successfully promoted attachment and proliferation of L929 cells over a 7-day culture with and without light activation, while triggering up to 2.5 and 4 log reduction in E. coli and S. mutans viability, respectively. These results support the therapeutic applicability of PAFs for frequently encountered bacterial infections, opening up new opportunities in photodynamic fibrous systems with integrated wound healing and infection control capabilities.
Collapse
Affiliation(s)
- Amy Contreras
- Institute of Medical and Biological Engineering, University of Leeds, Leeds LS2 9JT, UK; (A.C.); (M.J.R.)
| | - Michael J. Raxworthy
- Institute of Medical and Biological Engineering, University of Leeds, Leeds LS2 9JT, UK; (A.C.); (M.J.R.)
- Neotherix Ltd., The Hiscox Building, Peasholme Green, York YO1 7PR, UK
| | - Simon Wood
- School of Dentistry, St. James’s University Hospital, University of Leeds, Leeds LS9 7TF, UK;
| | - Giuseppe Tronci
- School of Dentistry, St. James’s University Hospital, University of Leeds, Leeds LS9 7TF, UK;
- Clothworkers Centre for Textile Materials Innovation for Healthcare, School of Design, University of Leeds, Leeds LS2 9JT, UK
| |
Collapse
|